Guardion Health Sciences (GHSI) 10-K 14 Feb 19 2018 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Feb. 08, 2019	Jun. 30, 2018
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	FY
Entity Registrant Name	Guardion Health Sciences, Inc.
Entity Central Index Key	1,642,375
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Public Float			$ 0
Entity Common Stock, Shares Outstanding		20,564,328
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Small Business	true

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Current assets
Cash	$ 670,948	$ 4,735,230
Accounts receivable	28,203	72,771
Inventories	357,997	154,730
Prepaid expenses	47,773	117,164
Total current assets	1,104,921	5,079,895
Deposits	11,751	10,470
Property and equipment, net	274,804	95,597
Deferred offering	270,000	0
Intangible assets, net	456,104	620,741
Goodwill	1,563,520	1,563,520
Total assets	3,681,100	7,370,223
Current liabilities
Accounts payable and accrued liabilities	413,925	311,236
Accrued expenses and deferred rent	81,412	12,043
Line of credit	0	30,535
Due to related parties	0	146,133
Total current liabilities	495,337	499,947
Commitments and contingencies
Stockholders' Equity
Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 and 0 shares issued and outstanding at December 31, 2018 and December 31, 2017	0	0
Common stock, $0.001 par value; 90,000,000 shares authorized; 20,564,328 and 20,091,761 shares issued and outstanding at December 31, 2018 and December 31, 2017	20,564	20,092
Additional paid-in capital	37,798,562	33,716,140
Accumulated deficit	(34,633,363)	(26,865,956)
Total stockholders' equity	3,185,763	6,870,276
Total liabilities and stockholders' equity	$ 3,681,100	$ 7,370,223

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	90,000,000	90,000,000
Common Stock, Shares, Issued	20,564,328	20,091,761
Common Stock, Shares, Outstanding	20,564,328	20,091,761

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenue
Medical foods	$ 332,795	$ 245,217
Vision testing diagnostics	609,358	192,132
Total revenue	942,153	437,349
Cost of goods sold
Medical foods	161,023	110,993
Vision testing diagnostics	237,156	64,477
Total cost of goods sold	398,179	175,470
Gross profit	543,974	261,879
Operating expenses
Research and development	231,847	259,463
Sales and marketing	1,520,862	599,926
General and administrative	4,934,986	4,683,932
Total operating expenses	6,687,695	5,543,321
Loss from operations	(6,143,721)	(5,281,442)
Other expenses:
Interest expense	2,289	23,727
Warrants - extension of expiration dates	1,621,397	0
Total other expenses	1,623,686	23,727
Net loss	(7,767,407)	(5,305,169)
Adjustments related to Series A and Series B convertible preferred stock:
Accretion of deemed dividend	0	(601,952)
Dividend declared	0	(308,628)
Net loss attributable to common shareholders	$ (7,767,407)	$ (6,215,749)
Net loss per common share – basic and diluted	$ (0.38)	$ (0.45)
Weighted average common shares outstanding – basic and diluted	20,188,628	13,934,196

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficiency) - USD ($)	Total	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2016	$ (345,574)	$ 1,705	$ 0	$ 12,342	$ 20,290,586	$ (20,650,207)
Beginning Balance (in shares) at Dec. 31, 2016		1,705,154	0	12,341,998
Fair value of common stock issued for acquisition	2,287,500	$ 0	$ 0	$ 1,525	2,285,975	0
Fair value of common stock issued for acquisition (in shares)		0	0	1,525,000
Issuance of common stock for services	657,791	$ 0	$ 0	$ 325	657,466	0
Issuance of common stock for services (in shares)		0	0	324,650
Sale of common stock	5,000,001	$ 0	$ 0	$ 2,174	4,997,827	0
Sale of common stock (in shares)		0	0	2,173,914
Issuance of preferred stock	3,105,000	$ 0	$ 3,105	$ 0	3,101,895	0
Issuance of preferred stock (in shares)		0	3,105,000	0
Conversion of preferred stock	0	$ (1,705)	$ (3,105)	$ 3,491	1,319	0
Conversion of preferred stock (in shares)		(1,705,154)	(3,105,000)	3,490,977
Fair value of vested stock options	1,457,527	$ 0	$ 0	$ 0	1,457,527	0
Fair value of common stock issued upon conversion of notes payable and related interest	13,200	$ 0	$ 0	$ 9	13,191	0
Fair value of common stock issued upon conversion of notes payable and related interest (in shares)		0	0	9,041
Accretion of beneficial conversion feature on preferred stock	0	$ 0	$ 0	$ 0	601,952	(601,952)
Dividend on preferred stock	0	$ 0	$ 0	$ 226	308,402	(308,628)
Dividend on preferred stock (in shares)		0	0	226,181
Net loss	(5,305,169)	$ 0	$ 0	$ 0	0	(5,305,169)
Ending Balance at Dec. 31, 2017	6,870,276	$ 0	$ 0	$ 20,092	33,716,140	(26,865,956)
Ending Balance (in shares) at Dec. 31, 2017		0	0	20,091,761
Issuance of common stock – warrant exercises	16,460	$ 0	$ 0	$ 102	16,358	0
Issuance of common stock – warrant exercises (in shares)		0	0	103,000
Sale of common stock	850,000	$ 0	$ 0	$ 370	849,630	0
Sale of common stock (in shares)		0	0	369,567
Fair value of vested stock options	1,595,037	$ 0	$ 0	$ 0	1,595,037	0
Warrants - extension of expiration dates	1,621,397	0	0	0	1,621,397	0
Net loss	(7,767,407)	0	0	0	0	(7,767,407)
Ending Balance at Dec. 31, 2018	$ 3,185,763	$ 0	$ 0	$ 20,564	$ 37,798,562	$ (34,633,363)
Ending Balance (in shares) at Dec. 31, 2018		0	0	20,564,328

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Operating Activities
Net loss	$ (7,767,407)	$ (5,305,169)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	295,672	118,821
Accrued interest expense included in notes payable	0	(8,818)
Stock-based compensation	1,595,037	1,932,268
Stock-based compensation – related parties	0	183,051
Warrants – extension of expiration dates	1,621,397	0
(Increase) decrease in -
Accounts receivable	44,568	(20,993)
Inventories	(203,267)	(17,439)
Deposits and prepaid expenses	68,111	(87,251)
Increase (decrease) in -
Accounts payable and accrued expenses	102,689	(121,919)
Accrued and deferred rent costs	69,369	(76,247)
Net cash used in operating activities	(4,173,831)	(3,403,696)
Investing Activities
Purchase of property and equipment	(260,243)	(37,280)
Purchase of intellectual property	(50,000)	0
Cash assumed upon acquisition	0	4,895
Net cash used in investing activities	(310,243)	(32,385)
Financing Activities
Proceeds from issuance of promissory notes	0	100,000
Payments on promissory notes	0	(149,000)
Proceeds from issuance of preferred stock	0	3,105,000
Proceeds from issuance of common stock	850,000	5,000,001
Proceeds from exercise of warrants	16,460	0
Payments on line of credit	(30,535)	(1,860)
Deferred financing costs of IPO	(270,000)	0
(Decrease) increase in due to related parties	(146,133)	54,650
Net cash provided by financing activities	419,792	8,108,791
Cash:
Net (decrease) increase	(4,064,282)	4,672,710
Balance at beginning of period	4,735,230	62,520
Balance at end of period	670,948	4,735,230
Supplemental disclosure of cash flow information:
Cash paid for - Interest	0	23,532
Cash paid for - Income taxes	0	0
Non-cash financing activities:
Issuance of common stock dividends on preferred stock	0	308,628
Issuance of common stock upon conversion of notes payable and related interest	0	13,562
Fair value of common shares issued for acquisition allocated to:
Intangible assets	0	674,400
Goodwill	0	1,563,520
Other assets	$ 0	$ 49,580

Organization and Business Opera

Organization and Business Operations	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Organization and Business Operations Organization and Business Guardion Health Sciences, Inc. (the “Company”) was formed in December 2009 as a California limited liability company under the name P4L Health Sciences, LLC. On June 30, 2015, the Company converted from a California limited liability company to a Delaware corporation, changing its name from Guardion Health Sciences, LLC to Guardion Health Sciences, Inc. The Company is a specialty health sciences company that develops, formulates and distributes condition-specific medical foods with an initial medical food product on the market under the brand name Lumega-Z ® The Company also developed a proprietary medical device called the MapcatSF ® On September 29, 2017, the Company completed its acquisition of substantially all of the assets and certain liabilities of VectorVision, Inc., a company that specializes in the standardization of contrast sensitivity, glare sensitivity, low contrast acuity, and ETDRS visual acuity testing. VectorVision develops, manufactures and sells equipment and supplies for standardized vision testing. In August 2018, the Company created a wholly owned subsidiary, Transcranial Doppler Solutions, Inc. (“TDSI”). TDSI will be dedicated to the pursuit of early predictors resulting in, the Company believes, valuable therapeutic intervention for practitioners and their patients, and additional revenue streams generated from the testing and sale of Company products to appropriate customers. The Company is currently setting up the operations of TDSI and hopes to launch its services in upcoming quarters. The Company has had limited operations to date and has been primarily engaged in research and development, product commercialization and capital raising activities. Going Concern and Liquidity The financial statements have been prepared assuming the Company will continue as a going concern. The Company has utilized cash in operating activities of $4,173,831 and $3,403,696 during the years ended December 31, 2018 and 2017, respectively, and had an accumulated deficit of $34,633,363 as of December 31, 2018. The Company expects to continue to incur net losses and negative operating cash flows in the near-term. As a result, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the consolidated financial statements are issued. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern. The Company will continue to incur significant expenses for commercialization activities related to its lead product Lumega-Z, the MapcatSF medical device, and with respect to efforts to build the Company’s infrastructure. Development and commercialization of medical foods and medical devices involves a lengthy and complex process. Additionally, the Company’s long-term viability and growth may depend upon the successful development and commercialization of products other than Lumega-Z and the MapcatSF. The Company is continuing attempts to raise additional debt and/or equity capital to fund future operations, but there can be no assurances that the Company will be able to secure such additional financing in the amounts necessary to fully fund its operating requirements on acceptable terms or at all. If the Company is unable to access sufficient capital resources on a timely basis, the Company may be forced to reduce or discontinue its technology and product development programs and curtail or cease operations. Reverse Stock Split On January 30, 2019, following stockholder and Board approval, the Company filed a Certificate of Amendment to its Amended Certificate of Incorporation, as amended (the “Amendment”), with the Secretary of State of the State of Delaware to effectuate a one-for-two (1:2) reverse stock split (the “Reverse Stock Split”) of its common stock, par value $0.001 per share, without any change to its par value. The Amendment became effective on the filing date. The number of shares authorized for common and preferred stock were not affected by the Reverse Stock Split. No fractional shares were issued in connection with the Reverse Stock Split as all fractional shares were “rounded up” to the next whole share. Proportional adjustments for the Reverse Stock Split were made to the Company’s outstanding common stock, stock options, and warrants as if the split occurred at the beginning of the earliest period presented.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Use of Estimates Our financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The preparation of our financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the financial statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions used in valuing assets acquired in business acquisitions, impairment testing of long-term assets, accruals for potential liabilities, valuing equity instruments issued during the period, and realization of deferred tax assets. Actual results could differ from those estimates. Certain prior period amounts have been reclassified to conform to current period presentation. Such amounts consist of operating segment disclosures, whereby revenue and cost of goods sold have been broken out on the Consolidated Statements of Operations to conform with the Company’s two reportable business segments as of December 31, 2018. Fair Value of Financial Instruments The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as noted below. Disclosure as to transfers into and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required. Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives. Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges. Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded, non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models. The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end. The Company believes the carrying amount of its financial instruments (consisting of cash, accounts receivable, and accounts payable and accrued liabilities) approximates fair value due to the short-term nature of such instruments. The fair value of the Company’s line of credit approximates its carrying value given the interest rate of such line of credit. Concentration of Credit Risk and Other Risks and Uncertainties Cash balances are maintained at large, well-established financial institutions. At times, cash balances may exceed federally insured limits. Insurance coverage limits are $250,000 per depositor at each financial institution. The Company has never experienced any losses related to these balances. During the year ended December 31, 2018, the Vision Testing Diagnostics segment had one customer who accounted for approximately 47% 30% of the Company's sales. No other customer accounted for more than 10% of sales in either year. Accounts Receivable The Company evaluates the collectability of its trade accounts receivable based on multiple factors. In circumstances where the Company becomes aware of a specific customer’s inability to meet its financial obligations to the Company, a specific reserve for bad debts is estimated and recorded, which reduces the recognized receivable to the estimated amount the Company believes will ultimately be collected. In addition to specific customer identification of potential bad debts, bad debt charges are recorded based on the Company’s historical losses and an overall assessment of past due trade accounts receivable outstanding. The allowance for doubtful accounts and returns is established through a provision reducing the carrying value of receivables. At December 31, 2018 and 2017, no allowance for doubtful accounts and returns was considered necessary. Inventories The Company’s inventories are stated at the lower of weighted-average cost or market. The cost of finished goods and raw materials is determined on a first-in, first-out basis. The Company evaluates its inventories for obsolescence and recoverability at each reporting period. Property and Equipment Property and equipment are initially recorded at their historical cost. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from three to seven years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term. Management assesses the carrying value of property and equipment whenever events or changes in circumstances indicate that the carrying value may not be recoverable. If there is indication of impairment, management prepares an estimate of future cash flows expected to result from the use of the asset and its eventual disposition. If these cash flows are less than the carrying amount of the asset, an impairment loss is recognized to write down the asset to its estimated fair value. As of December 31, 2018 and 2017, the Company was not aware of the existence of any indicators of impairment at such dates. Intangible Assets In connection with the VectorVision transaction, the Company identified and allocated estimated fair values to intangible assets including goodwill and customer relationships. In accordance with Accounting Standard Codification (“ASC”) 350 – Intangibles – Goodwill and Other, the Company determined whether these assets are expected to have indefinite (such as goodwill) or limited useful lives, and for those with limited lives, the Company established an amortization period and method of amortization. Its goodwill and other intangible assets are subject to periodic impairment testing. The Company utilized the services of an independent third-party valuation firm to assist in identifying intangible assets and in estimating their fair values. The useful lives for the Company’s intangible assets other than goodwill were estimated based on Management’s consideration of various factors, including assumptions that market participants might use about sales expectations as well as potential effects of obsolescence, competition, technological progress and the regulatory environment. Because the future pattern in which the economic benefits of these intangible assets may not be reliably determined, amortization expense is generally calculated on a straight-line basis. Amortization expense for the identifiable intangible assets associated with the VectorVision acquisition is approximately $54,000 per quarter and is included with general and administrative expenses in the Company’s Statements of Operations. The Company reviews all intangible assets for impairment when circumstances indicate that their carrying values may not be recoverable. If the carrying value of an asset group is not recoverable, the Company recognizes an impairment loss for the excess carrying value over the fair value in its consolidated statements of operations. As of December 31, 2018 and 2017, the Company was not aware of the existence of any indicators of impairment of its intangibles at such dates. Goodwill Goodwill represents the excess of the purchase consideration over the fair value of the net tangible and identifiable intangible assets acquired in a business combination. The Company evaluates goodwill for impairment on an annual basis or whenever events and changes in circumstances suggest that the carrying amount may not be recoverable. The Company conducts its annual impairment analysis in the beginning of the fourth quarter of each fiscal year. Impairment of goodwill is tested at the reporting unit level by comparing the reporting unit’s carrying amount, including goodwill, to the fair value of the reporting unit. Estimations and assumptions regarding the number of reporting units, future performances, results of the Company’s operations and comparability of its market capitalization and net book value will be used. If the carrying amount of the reporting unit exceeds its fair value, goodwill is considered impaired and an impairment loss is measured by the resulting amount. Because the Company has one reporting unit, the Company utilizes an entity-wide approach to assess goodwill for impairment. As of December 31, 2018 and 2017, the Company was not aware of the existence of any indicators of impairment of its goodwill at such dates. Deferred Offering Costs Deferred offering costs consist principally of legal, accounting, and underwriters’ fees incurred related to the planned underwritten public offering of the Company’s Common Stock. These deferred offering costs will be charged against the gross proceeds received or will be charged to expense if the offering is not completed. Revenue Recognition The Company’s revenue is comprised of sales of medical foods and dietary supplements to consumers through a direct sales/credit card process. In addition, the Company sells medical device equipment and supplies to customers both in the U.S. and internationally. Through December 31, 2017, the Company recognized revenue when risk of loss transferred to its customers and collection of the receivable was reasonably assured, which generally occurred when the product was shipped. A product is not shipped without an order from the customer and credit acceptance procedures performed. The Company allows for returns within 30 days of purchase, although for all periods presented, returns have been insignificant. On January 1, 2018. the Company adopted ASU 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09” or “Topic 606”) and all related amendments and applied the concepts to all contracts using the full retrospective method. The new standard provides authoritative guidance clarifying the principles for recognizing revenue and developing a common revenue standard for U.S. generally accepted accounting principles. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods and services to customers in an amount that reflects the consideration to which the entity expects to be entitled in the exchange for those goods or services. Under the new guidance, revenue is recognized when control of promised goods or services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company reviews its sales transactions to identify contractual rights, performance obligations, and transaction prices, including the allocation of prices to separate performance obligations, if applicable. Revenue and costs of sales are recognized once products are delivered to the customer’s control and performance obligations are satisfied. Due to the nature of the products sold by the Company, the adoption of the new standard has had no quantitative effect on the financial statements and the Company had no cumulative impact of adopting Topic 606 to record through accumulated deficit. However, the guidance requires additional disclosures to help readers of financial statements better understand the nature, amount, timing, and uncertainty of revenue that is recognized. All products sold by the Company are distinct individual products and consist of medical foods, supplemental formulas, medical devices and related supplies. The products are offered for sale as finished goods only, and there are no performance obligations required post-shipment for customers to derive the expected value from them. Contracts with customers contain no incentives or discounts that could cause revenue to be allocated or adjusted over time. Control of products sold transfers to customers upon shipment from the Company’s facilities, and the Company’s performance obligations are satisfied at that time. Shipping and handling activities are performed before the customer obtains control of the goods and therefore represent a fulfillment activity rather than a promised service to the customer. Payment for sales of Lumega-Z is generally made by approved credit cards. Payments for medical device sales are generally made by check, credit card, or wire transfer. Historically the Company has not experienced any significant payment delays from customers. The Company provides a 30-day right of return to its retail Lumega-Z customers. A right of return does not represent a separate performance obligation, but because customers are allowed to return products, the consideration to which the Company expects to be entitled is variable. Upon evaluation of historical Lumega-Z and VectorVision product returns, the Company determined that less than one percent of products is returned, and therefore believes it is probable that such returns will not cause a significant reversal of revenue in the future. Due to the insignificant amount of historical returns as well as the standalone nature of the Company’s products and assessment of performance obligations and transaction pricing for the Company’s sales contracts, the Company does not currently maintain a contract asset or liability balance at this time. The Company assesses its contracts and the reasonableness of its conclusions on a quarterly basis. The following table presents the Company’s revenues disaggregated by segment: Year Ended December 31, 2018 2017 Medical foods $ 332,795 $ 245,217 Vision testing diagnostics 609,358 192,132 $ 942,153 $ 437,349 Research and Development Costs Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s medical foods and related products. Research and development expenditures, which include stock compensation expense, are expensed as incurred and totaled $231,847 and $259,463 for the years ended December 31, 2018 and 2017, respectively. Patent Costs The Company is the owner of three issued domestic patents, two pending domestic patent applications, one issued foreign patent in Europe, and three foreign patent applications in Canada, Europe and Hong Kong. Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and any related patent applications, patent costs, including patent-related legal fees, filing fees and internally generated costs, are expensed as incurred. During the years ended December 31, 2018 and 2017, patent costs were $93,149 and $30,789, respectively, and are included in general and administrative costs in the statements of operations. Stock-Based Compensation The Company periodically issues stock-based compensation to officers, directors, contractors and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date. Stock-based payments to officers, directors, consultants, contractors, and employees, which include grants of employee stock options, are recognized in the financial statements based on their fair values. Stock option grants, which are generally time vested, will be measured at the grant date fair value and charged to operations on a straight-line basis over the vesting period. The fair value of stock options is determined utilizing the Black-Scholes option-pricing model, which is affected by several variables, including the risk-free interest rate, the expected dividend yield, the expected life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date and the estimated volatility of the common stock over the term of the equity award. The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance of the FASB whereby the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period using a graded vesting basis. In certain circumstances where there are no future performance requirements by the non-employee, grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date. The Company recognizes stock compensation expense, on stock purchases at a price less than fair value, and for fully-vested stock issued to consultants and other service providers, for the excess of fair value of the stock over the price paid for the stock. The Company recognizes the fair value of stock-based compensation within its statements of operations with classification depending on the nature of the services rendered. The Company will issue new shares to satisfy stock option exercises. Income Taxes The Company currently accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities. The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company determines that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made. The Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company’s net operating losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which the Company currently operates or has operated in the past. The Company had no unrecognized tax benefits as of December 31, 2018 and 2017 and does not anticipate any material amount of unrecognized tax benefits within the next 12 months. The Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The tax effects of a position are recognized only if it is “more-likely-than-not” to be sustained by the taxing authority as of the reporting date. If the tax position is not considered “more-likely-than-not” to be sustained, then no benefits of the position are recognized. As of December 31, 2018, the Company had not recorded any liability for uncertain tax positions. In subsequent periods, any interest and penalties related to uncertain tax positions will be recognized as a component of income tax expense. On December 22, 2017, the President of the United States signed and enacted into law H.R. 1 (the “Tax Reform Law”). The Tax Reform Law, effective for tax years beginning on or after January 1, 2018, except for certain provisions, resulted in significant changes to existing United States tax law, including various provisions that will impact the Company. The Tax Reform Law reduces the federal corporate tax rate from 35% to 21% effective January 1, 2018. The Company will continue to analyze the provisions of the Tax Reform Law to assess the impact to the Company’s consolidated financial statements. Net Loss per Share The Company’s computation of basic and diluted net loss per common share is measured as net loss divided by the weighted average common shares outstanding during the respective periods, excluding unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Potential common shares such as from unexercised warrants, options, and shares associated with convertible debt outstanding that have an anti-dilutive effect are excluded from the calculation of diluted net loss per share. The Company’s basic and diluted net loss per share is the same for all periods presented because all shares issuable upon exercise of warrants and conversion of convertible debt outstanding are anti-dilutive as they decrease loss per share. The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive: December 31, 2018 2017 Warrants 1,230,674 1,491,833 Options 1,362,500 1,062,500 2,593,174 2,554,333 Recent Accounting Pronouncements In February 2016, the FASB issued Accounting Standards Update No. 2016-02 (ASU 2016-02), Leases (Topic 842). ASU 2016-02 requires a lessee to record a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, on the balance sheet for all leases with terms longer than 12 months, as well as the disclosure of key information about leasing arrangements. ASU 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. ASU 2016-02 requires classification of all cash payments within operating activities in the statement of cash flows. Disclosures are required to provide the amount, timing and uncertainty of cash flows arising from leases. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. ASU 2016-02 has subsequently been amended and modified by ASU 2018-10 (codification improvements), 2018-11 (implementation improvements) and 2018-20 (scope revisions). ASU 2016-02 (including the subsequent amendments and modifications) is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. The Company is evaluating the impact of the adoption of ASU 2016-02 on the Company’s financial statement presentation and disclosures and expects the most significant change will be the recognition of right-to-use assets and lease liabilities on its balance sheet for real estate operating lease commitments. In July 2017, the FASB issued Accounting Standards Update No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features; (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception (“ASU 2017-11”). ASU 2017-11 allows companies to exclude a down round feature when determining whether a financial instrument (or embedded conversion feature) is considered indexed to the entity’s own stock. As a result, financial instruments (or embedded conversion features) with down round features may no longer be required to be accounted for as derivative liabilities. A company will recognize the value of a down round feature only when it is triggered and the strike price has been adjusted downward. For equity-classified freestanding financial instruments, an entity will treat the value of the effect of the down round as a dividend and a reduction of income available to common shareholders in computing basic earnings per share. For convertible instruments with embedded conversion features containing down round provisions, entities will recognize the value of the down round as a beneficial conversion discount to be amortized to earnings. ASU 2017-11 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The guidance in ASU 2017-11 is to be applied using a full or modified retrospective approach. The adoption of ASU 2017-11 is not currently expected to have any impact on the Company’s financial statement presentation or disclosures. In June 2018, the FASB issued Accounting Standards Update 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”). ASU 2018-07 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. ASU 2018-07 also clarifies that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Revenue from Contracts with Customers (Topic 606). ASU 2018-07 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company will adopt the provisions of ASU 2018-07 in the quarter beginning January 1, 2019. The adoption of ASU 2018-07 is not expected to have a material impact on the Company’s financial statement presentation or disclosures. The Company’s management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

Segment Reporting

Segment Reporting	12 Months Ended
	Dec. 31, 2018
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	3. Segment Reporting The Company determined its reporting units in accordance with ASC 280, “Segment Reporting” (“ASC 280”). The Company historically has reported its operating results as a single reportable segment described as the business of developing and commercializing a variety of products that support the detection, intervention and monitoring of a range of eye diseases. The Company’s chief executive officer, who is the Chief Operating Decision Maker (“CODM”), has historically reviewed financial information on an aggregated basis for purposes of allocating resources and evaluating financial performance. In September 2017, the Company, through its wholly-owned subsidiary VectorVision Ocular Health, Inc., acquired substantially all of the assets and certain liabilities of VectorVision, Inc., a company that specializes in the standardization of contrast sensitivity, glare sensitivity, low contrast acuity, and early treatment diabetic retinopathy study (“ETDRS”) visual acuity testing. In August 2018, the Company created a wholly owned subsidiary, Transcranial Doppler Solutions, Inc. (“TDSI”). The Company is currently setting up the operations of TDSI and hopes to launch its services in upcoming quarters. Although all of the Company’s products and services target the early detection, intervention and monitoring of a range of eye diseases, the addition of potential new products or services as the Company grows requires Management to periodically reevaluate its reporting structure. As sales of our medical food as well as sales of VectorVision products grow, there is an increased need for the CODM to evaluate revenue and gross profit on a product line or group basis for purposes of resource allocation. As of December 31, 2018, the TDSI subsidiary does not meet the required quantitative criteria to be considered a reportable operating segment. Additionally, TDSI does not share similar economic characteristics or a majority of the aggregation criteria set forth in ASC 280, and therefore is shown as “All other (TDSI)” below. As of December 31, 2018, based on anticipated growth and the expanding diversity of product and service offerings by the Company, Management has concluded that results should be reported in two operating segments: Medical Foods, and Vision Testing Diagnostics. For the Year Ended December 31, 2018 Corporate Medical Foods Vision Testing Diagnostics Total Revenue $ - $ 332,795 $ 609,358 $ 942,153 Cost of goods sold - 161,023 237,156 398,179 Gross profit - 171,772 372,202 543,974 Operating expenses 2,707,924 3,566,835 412,936 6,687,695 Loss from operations $ (2,707,924 ) $ (3,395,063 ) $ (40,734 ) $ (6,143,721 ) For the Year Ended December 31, 2017 Corporate Medical Foods Vision Testing Diagnostics Total Revenue $ - $ 245,217 $ 192,132 $ 437,349 Cost of goods sold - 110,993 64,477 175,470 Gross profit - 134,224 127,655 261,879 Operating expenses 2,865,513 2,595,776 82,032 5,543,321 Loss from operations $ (2,865,513 ) $ (2,461,552 ) $ 45,623 $ (5,281,442 ) The following tables set forth our total assets by segment. Intersegment balances and transactions have been removed: As of December 31, 2018 Corporate Medical Foods Vision Testing Diagnostics Total Current assets Cash $ - $ 552,613 $ 118,335 $ 670,948 Inventories - 235,957 122,040 357,957 Other - 44,110 31,866 75,976 Total current assets - 832,680 272,241 1,104,921 Property and equipment, net - 264,178 10,626 274,804 Deferred offering 270,000 - - 270,000 Intangible assets, net 456,104 - - 456,104 Goodwill 1,563,520 - - 1,563,520 Other - 11,751 - 11,751 Total assets $ 2,289,624 $ 1,108,609 $ 282,867 $ 3,681,100 As of December 31, 2017 Corporate Medical Foods Vision Testing Diagnostics Total Current assets Cash $ - $ 4,709,512 $ 25,718 $ 4,735,230 Inventories - 57,978 96,752 154,730 Other - 119,640 70,295 189,935 Total current assets - 4,887,130 192,765 5,079,895 Property and equipment, net - 86,723 8,874 95,597 Deferred offering - - - - Intangible assets, net 620,741 - - 620,741 Goodwill 1,563,520 - - 1,563,520 Other - 10,470 - 10,470 Total assets $ 2,184,261 $ 4,984,323 $ 201,639 $ 7,370,223

Inventories

Inventories	12 Months Ended
	Dec. 31, 2018
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	4. Inventories Inventories consisted of the following: December 31, 2018 2017 Raw materials $ 282,574 $ 133,354 Finished goods 75,423 21,376 $ 357,997 $ 154,730

Property and Equipment, net

Property and Equipment, net	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	5. Property and Equipment, net Property and equipment consisted of the following: December 31, 2018 2017 Leasehold improvements $ 98,357 $ 98,357 Testing equipment 249,447 150,603 Furniture and fixtures 163,186 50,300 Computer equipment 64,976 16,464 Office equipment 8,193 8,193 584,159 323,917 Less accumulated depreciation and amortization (309,355 ) (228,320 ) $ 274,804 $ 95,597 For the years ended December 31, 2018 and 2017, depreciation and amortization expense was $81,035 and $65,161, respectively, of which $34,524 and $29,574 was included in research and development expense, $10,898 and $0 was included in sales and marketing expense, and $35,613and $35,587 was included in general and administrative expense, respectively.

Acquisition of VectorVision

Acquisition of VectorVision	12 Months Ended
	Dec. 31, 2018
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	6. Acquisition of VectorVision On September 29, 2017, the Company, through a wholly-owned subsidiary, completed the acquisition of substantially all of the assets and liabilities of VectorVision, Inc., an Ohio corporation (“VectorVision”), in exchange for 1,525,000 shares of the Company’s common stock, valued at $2,287,500, pursuant to the terms of an Asset Purchase and Reorganization Agreement dated September 29, 2017, which agreement was entered into on an arm’s-length basis. The wholly-owned subsidiary that acquired the business is called VectorVision Ocular Health, Inc., a Delaware corporation, doing business as VectorVision. VectorVision’s assets acquired by the Company pursuant to the agreement included, among others, accounts receivable, fixed assets, inventories, trademarks and copyrights. VectorVision’s liabilities assumed by the Company included, among others, certain trade accounts payable to third parties and accrued liabilities, and amounts owed under an outstanding line of credit. With respect to the 1,525,000 shares of common stock, 125,000 shares were held back as security for VectorVision’s indemnification obligations to the Company and the remaining 1,400,000 shares were issued to VectorVision at the closing of the transaction. The shares represented approximately 11% of the Company’s issued and outstanding common stock immediately following consummation of the agreement. The shares held back as security are included in our weighted average common shares outstanding for per-share calculations. VectorVision develops, manufactures and sells equipment and supplies for standardized vision testing for use by eye doctors in clinical trials, for real-world vision evaluation, and industrial vision testing. VectorVision specializes in the standardization of contrast sensitivity, glare sensitivity, low contrast acuity, and ETDRS (Early Treatment Diabetic Retinopathy Study) visual acuity testing. VectorVision developed and commercialized its CSV-1000 medical device to conduct contrast sensitivity testing and it developed and commercialized its ESV-3000 medical device to conduct ETDRS visual acuity testing. The patented standardization system provides the practitioner or researcher with the ability to delineate very small changes in visual capability, either as compared to the population or from visit to visit. The Company believes VectorVision’s CSV-1000 device to be the standard of care for clinical trials. The acquisition of VectorVision expands the Company’s technical portfolio and the Company believes it further establishes the Company’s position at the forefront of early detection, intervention and monitoring of a range of eye diseases. The Company accounted for the acquisition pursuant to Accounting Standards Codification Topic 805, Business Combinations (“ASC 805”). Management identified and evaluated the fair values of the assets acquired, relying in part, on the work of an independent third party valuation firm engaged by the Company to provide input as to the fair value of the consideration paid (because there is no established trading market for the Company’s Common Stock) and the assets acquired, including the valuation methodology most relevant to the transactions described herein, and to assist in the related calculations, analysis and allocations. Historical transactions, as well as the income, market and cost approaches to value were considered. Management ultimately determined that due to recent sales of the Company’s preferred stock and consideration of current business and market factors, that the use of historical transactions, and a value of $1.50, would result in the most appropriate valuation for accounting purposes. In accordance with ASC 805, the Company utilized the acquisition method of accounting, whereby the purchase consideration is allocated to specific tangible and intangible assets at their estimated fair values on the date of acquisition. The following table summarizes the allocation of preliminary fair values of the purchase consideration to the assets and liabilities assumed: Fair Values Common stock consideration $ 2,287,500 Liabilities assumed 108,722 Total purchase consideration 2,396,222 Cash (4,895 ) Accounts receivable (50,105 ) Inventory (93,293 ) Prepaid assets (551 ) Property and equipment (9,458 ) Intangible assets (674,400 ) Goodwill $ 1,563,520 Goodwill is calculated as the excess of the consideration transferred over the net assets recognized and represents the expected revenue and benefits of the combined company. The Company has consolidated VectorVision’s operations with the Company’s statement of operations commencing October 1, 2017. The following unaudited pro forma financial information gives effect to the Company’s acquisition of VectorVision as if the acquisition had occurred on January 1, 2017 and had been included in the Company’s consolidated statements of operations during the year ended December 31, 2017: December 31, 2017 Pro forma net revenues $ 824,028 Pro forma operating expenses $ 6,087,726 Pro forma net loss attributable to common shareholders $ (6,500,590 ) Pro forma net loss per share $ (0.47 )

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Text Block]	7. Intangible Assets The Company’s finite-lived intangible assets consisted of the following: December 31, 2018 2017 Customer relationships $ 430,700 $ 430,700 Technology 161,100 161,100 Trade Names 65,600 65,600 Noncompetition 17,000 17,000 674,400 674,400 Less accumulated depreciation and amortization (268,296 ) (53,659 ) $ 406,104 $ 620,741 The Company’s amortization expense on its finite-lived intangible assets was $214,637 and $53,659 for the years ended December 31, 2018 and 2017, respectively. The Company estimates future amortization expense on its finite-lived intangible assets as of December 31, 2018 to be as follows: For Years Ended December 31, 2019 $ 214,637 2020 165,320 2021 16,307 2022 9,840 $ 406,104

Acquisition of Intellectual Pro

Acquisition of Intellectual Property	12 Months Ended
	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets Disclosure [Text Block]	8. Acquisition of Intellectual Property On January 26, 2018, the Company acquired the rights to the trademark GLAUCO-HEALTH as well as the name “International Eye Wellness Institute” (together, the “IP Assets”) from an unrelated third party. The purchase included all rights, title, and interest in and to the IP Assets, including (a) the right to register and use the IP Assets; (b) all goodwill associated with the IP Assets; (c) all income, royalties, and damages hereafter due or payable with respect to the IP Assets; (d) all rights to sue for past, present, and future infringements or misappropriations of the IP Assets; and I and all other intellectual property rights owned or claimed by the seller or embodied in the IP Assets. In exchange for these rights, the Company paid the seller $50,000 in cash. ASC 350-30-20 defines a defensive intangible asset as an acquired intangible asset in a situation in which an entity does not intend to actively use the asset but intends to hold (lock up) the asset to prevent others from obtaining access to the asset. The Company determined that the acquired intangible asset met the definition of a defensive intangible asset. The Company accounted for the $50,000 payment as an acquired intangible asset as of the closing of the agreement. As the Company can renew the underlying rights to the IP Assets indefinitely at nominal cost, the assets have been classified as a non-amortizable intangible asset on the Company’s balance sheet at September 30, 2018. The Company will evaluate the status of the assets for impairment annually or more frequently if warranted. On January 26, 2018 the Company entered into a consulting agreement with the principal of the seller to assist with the development of the IP Assets and other assets acquired by the Company in the transaction. In conjunction with the consulting agreement, the Company granted a stock option on January 26, 2018 to the consultant to purchase a total of 250,000 shares of the common stock of the Company (See Note 10).

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	9. Commitments and Contingencies Operating Lease In October 2012, the Company entered into a lease agreement for 9,605 square feet of office and warehouse space commencing March 1, 2013. Upon entering into the agreement, the Company paid a deposit of $47,449, of which $36,979 represented prepaid rent. As of December 31, 2018, $10,470 remained on deposit under the lease agreement. The lease agreement was renewed for an additional five years in 2018. As of December 31, 2018, remaining average monthly lease payments under the amended lease agreement were $12,816 through July 2023. In connection with the acquisition of VectorVision on September 29, 2017, the Company assumed a lease agreement for 5,000 square feet of office and warehouse space commencing October 1, 2017. The lease was renewed for an additional 65 months. As of December 31, 2018, remaining average monthly lease payments are $1,825 through February 2023. As of December 31, 2018 and 2017, the Company had accrued and deferred rent payable for its office and warehouse facilities under its lease agreements in the aggregate of $3,712. The approximate future minimum lease payments under non-cancelable operating leases at December 31, 2018 are as follows: Years ending December 31, 2019 $ 166,770 2020 171,767 2021 176,933 2022 182,249 2023 and thereafter 98,417 $ 796,136 Rent expense was $192,624 and $157,751 for the years ended December 31, 2018 and 2017, respectively. Contingencies The Company is periodically the subject of various pending or threatened legal actions and claims arising out of its operations in the normal course of business. In the opinion of management of the Company, adequate provision has been made in the Company’s financial statements at December 31, 2018 with respect to such matters, including the matter noted below. On or about July 26, 2017, the Company received a payment demand from a former consultant to the Company alleging that the consultant was owed approximately $192,000 for services rendered. The Company disputed the demand whereby the Company filed a lawsuit on January 29, 2018 against the consultant and its related entities in the United States District Court for the Southern District of California seeking declaratory relief regarding advisory fees and ownership interest in the Company. The parties settled the disputes in their entirety and the case was dismissed with prejudice on August 29, 2018.

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit)	12 Months Ended
	Dec. 31, 2018
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	10. Stockholders’ Equity (Deficit) Preferred Stock Series A During 2016, the Company sold 1,170,000 shares of the Company's Series A Senior Convertible Preferred Stock (the "Series A Preferred Stock") to various investors. The purchase price of the Series A Preferred Stock was $1.00 per share, for an aggregate purchase price of $1,170,000. In addition, during 2016, the Company issued 535,154 shares of its Series A Preferred Stock with a fair value of $784,888 upon conversion of $535,149 of notes payable and accrued interest. The Series A Preferred Stock had a stated value of $1.00 per share and accrued an annual dividend at the rate of 8% of the stated value, calculated quarterly, paid in shares of common stock at the rate of $1.20 per share. During the year ended December 31, 2017, the Company declared dividends of $122,328 on its Series A Preferred Stock which were satisfied in full through the issuance of an aggregate of 101,962 shares of common stock. Series B Beginning in March 2017 and through September 30, 2017, the Company sold 3,105,000 shares of the Company's Series B Convertible Preferred Stock (the "Series B Preferred Stock") to various investors. The purchase price of the Series B Preferred Stock was $1.00 per share, for an aggregate purchase price of $3,105,000. The Series B Preferred Stock had a stated value of $1.00 per share and accrued an annual dividend at the rate of 6% of the stated value, calculated quarterly, paid in shares of common stock at the rate of $1.50 per share. During the year ended December 31, 2017, the Company declared dividends of $186,300 on its Series B Preferred Stock which were satisfied in full through the issuance of an aggregate of 124,219 shares of common stock. Preferred Stock Conversion Event On November 3, 2017, the Company completed the issuance and sale of an aggregate of 2,173,914 shares of common stock (see below). The completion of the private placement triggered, at the Company's election, the automatic conversion of the Series A Preferred Stock and the Series B Preferred Stock into shares of common stock. Accordingly, immediately following the completion of the private placement, the Company effected the conversion of all outstanding shares of Series A Preferred Stock and the Series B Preferred Stock into 3,490,977 shares of common stock effective November 3, 2017. On April 26, 2018, the Company filed a Certificate of Elimination with the Secretary of the State of Delaware, withdrawing the respective Certificates of Designation that established the right, privileges and preferences of the Series A Preferred Stock and Series B Preferred Stock, thereby making all 10,000,000 authorized shares of preferred stock available for issuance. Common Stock Sale of shares During the period from November 26, 2018 through December 31, 2018, the Company completed the issuance and sale of an aggregate of 369,567 shares of common stock, par value $0.001 per share, at a purchase price of $2.30 per share. Total gross proceeds were $850,000. These shares were sold in a private placement to certain purchasers pursuant to Stock Purchase Agreements. On November 3, 2017, the Company completed the issuance and sale of an aggregate of 2,173,914 shares of common stock, par value $0.001 per share, at a purchase price of $2.30 per share. Total gross proceeds were $5,000,001. These shares were sold in a private placement to certain purchasers pursuant to a Stock Purchase Agreement dated as of November 3, 2017. Shares issued with vesting requirements The Company periodically issues shares of common stock that vest over time to service providers. As of December 31, 2016, there were 176,250 of previously issued shares of restricted common stock to service providers valued at $113,754 that had not yet vested. During 2017, the Company issued an additional 81,250 shares of restricted common stock for services rendered. These shares were subject to vesting requirements over 6 months and subject to forfeiture if vesting conditions were not met. The aggregate fair value of the stock was $143,000 based on a valuation per share of $1.76 on the date of grant. During 2017, the Company recorded $256,754 expense related to the vested portion of restricted stock issued in 2017. As of December 31, 2017, all shares had vested. Additional details of the Company’s restricted common stock are as follows: Number of Shares Fair Value Weighted Average Grant Date Fair Value Per Share Non-vested, December 31, 2016 176,250 $ 113,754 $ 2.26 Issued 81,250 143,000 1.76 Vested (257,500 ) (256,754 ) 2.10 Forfeited - - - Non-vested, December 31, 2017 - $ - $ - Other issuances During 2017, the Company also issued 243,400 fully vested shares of common stock for services rendered. During the year ended December 31, 2017, the Company recognized $401,037 in stock compensation expense related to these shares. Warrants A summary of the Company’s warrant activity is as follows: Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) December 31, 2016 1,461,836 $ 0.88 2.19 Granted 30,000 0.03 0.04 Forfeitures - - - Expirations - - - Exercised - - - December 31, 2017 1,491,836 0.89 1.16 Granted - - - Forfeitures - - - Expirations (158,162 ) 0.17 - Exercised (103,000 ) 0.01 - December 31, 2018, all exercisable 1,230,674 $ 0.71 0.29 The exercise prices of warrants outstanding and exercisable as of December 31, 2018 are as follows: Warrants Outstanding and Exercisable (Shares) Exercise Prices 876,250 $ 0.50 70,000 1.00 30,000 1.50 254,424 2.00 1,230,674 In January 2018, an investor exercised warrants for 73,000 shares of common stock. The warrants were exercisable for $0.02 per share, and the Company received $1,460 in cash. The Company issued the shares and recorded the cash received as additional equity. In December 2018, an investor exercised warrants for 30,000 shares of common stock. The warrants were exercisable for $0.50 per share, and the Company received $15,000 in cash. The Company issued the shares and recorded the cash received as additional equity. On April 30, 2018, The Company offered a one-month exercise period extension to stockholders who held warrants to purchase shares of common stock of the Company that were scheduled to expire on May 1, 2018. Pursuant to the terms of a Note and Warrant Purchase Agreement entered into by the Company and such holders, such warrants were issued upon the conversion of certain promissory notes into common stock on May 1, 2015. Four of the warrant holders did not extend their warrants, resulting in the expiration of 75,503 warrants on May 1, 2018. Six warrant holders extended the term of an aggregate of 201,543 warrants by one month to June 1, 2018. The exercise price of such warrants is $2.00 per share. On May 31, 2018, the six warrant holders noted above were offered a further extension of the exercise period for their warrants. One holder did not extend, resulting in the expiration of 15,119 warrants on June 1, 2018. The Company and five warrant holders extended the term of an aggregate of 186,424 warrants. These warrants are now scheduled to expire on the earlier of (a) May 31, 2019 or (b) sixty days following the date on which the common stock of the Company becomes listed or approved for listing on a national securities exchange. The exercise price of such warrants remains unchanged at $2.00 per share, but cashless exercise provisions have been eliminated from such warrants. On September 21, 2018, the Company extended the expiration date of warrants to purchase shares of common stock of the Company that were scheduled to expire at dates ranging from September 30, 2018 through January 25, 2019 held by two stockholders. Pursuant to the terms of a Promissory Note and Loan Agreements entered into by the Company and such holders, the warrants were originally issued as inducement to lend money to the Company. The warrant holders extended the expiration dates of an aggregate of 300,000 warrants. These warrants are now scheduled to expire on February 15, 2019. The exercise price of $0.50 per share and all other terms of the warrants remain unchanged. Management applied the guidance in ASC 718 – Compensation-Stock Compensation which indicates that a modification to the terms of an award should be treated as an exchange of the original award for a new award with the resulting total compensation cost equal to the grant-date fair value of the original award plus the incremental value of the modification to the award. Under ASC 718, the calculation of the incremental value is based on the excess of the fair value of the new (modified) award based on current circumstances over the fair value of the original award measured immediately before its terms are modified based on current circumstances. The Company recognized expense of $1,621,397 during the year ended December 31, 2018 relating to the extension of the exercise periods of the warrants based upon a Black-Scholes option-pricing model using stock prices of $2.30 and $4.00, volatility of 118% and 119%, and average risk-free rates of 2.61 and 2.89. The expense is reflected as Warrants - extension of expiration dates in the Company’s statements of operations. As of December 31, 2018, the Company had an aggregate of 1,230,674 outstanding warrants to purchase shares of its common stock with a weighted average exercise price of $0.71, weighted average remaining life of 0.3 years and aggregate intrinsic value of $3,860,723, based upon a stock valuation of $4.00 per share. The intrinsic value is calculated as the difference between the market value of the underlying common stock and the exercise price of the warrants. Stock Options A summary of the Company’s stock option activity is as follows: Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) December 31, 2016 - - - Granted 1,062,500 $ 2.19 5.14 Forfeitures - - - Expirations - - - Exercised - - - December 31, 2017 1,062,500 2.19 5.14 Granted 300,000 0.55 0.55 Forfeitures - - - Expirations - - - Exercised - - - December 31, 2018, outstanding 1,362,500 $ 2.26 3.78 December 31, 2018, exercisable 1,262,500 $ 2.26 3.78 The exercise prices of options outstanding and exercisable as of December 31, 2018 are as follows: Options Outstanding (Shares) Options Exercisable (Shares) Exercise Prices 625,000 625,000 $ 2.00 62,500 62,500 2.30 675,000 575,000 2.50 1,362,500 1,262,500 On September 30, 2017, the Company entered into a consulting agreement pursuant to which the Company granted a total of 625,000 common stock options. 325,000 of the options with a fair value of $486,070 vested immediately, and the remaining 300,000 options vested ratably over twelve months on a quarterly basis with compensation cost measured as the fair value at the end of each reporting period. The options are non-qualified, have an exercise price of $2.00 per share, and will expire 5 years from the grant date. As of December 31, 2017, the Company had recognized compensation cost of $658,383 relating to the vesting of 400,000 options. During the year ended December 31, 2018, the Company recognized stock compensation costs of $394,239 related to the vesting of 225,000 options based upon a graded vesting schedule. As of December 31, 2018, the 625,000 options were fully vested and exercisable. On November 30, 2017, the Company granted a total of 62,500 common stock options to an employee. The options, with a fair value of $143,750 vested immediately and are fully exercisable. The options are non-qualified, have an exercise price of $2.30 per share, and will expire 10 years from the grant date. On December 30, 2017, the Company entered into a consulting agreement pursuant to which the Company granted a total of 375,000 common stock options. 125,000 of the options with a fair value of $312,275 vested immediately, and the remaining 250,000 options vested ratably over six months on a quarterly basis with compensation cost measured as the fair value at the end of each reporting period, using a Black Scholes option-pricing model and a graded vesting schedule. The options are non-qualified, have an exercise price of $2.50 per share, and will expire 5 years from the grant date. During the year ended December 31, 2018, the Company recognized stock compensation costs of $413,877 related to the vesting of 250,000 options. As of December 31, 2018, the 375,000 options were fully vested and exercisable. On January 26, 2018, the Company entered into an agreement with a consultant to develop products based on certain intellectual property owned by the Company (see Note 8). In conjunction with the consulting agreement, the Company granted a stock option to the consultant to purchase a total of 250,000 shares of the common stock of the Company. 125,000 shares of the option with a fair value of $287,500 vested immediately, 62,500 shares vested on December 31, 2018 and the remaining 62,500 shares vest on December 31, 2019 provided the consultant is still an active service provider. As of December 31, 2018, the 62,500 options that remain to vest were valued in total at $249,777 based upon a Black-Scholes option-pricing model. Compensation cost is measured as the fair value at the end of each reporting period and cost is amortized based upon a graded vesting schedule. The options are non-qualified, have an exercise price of $2.50 per share, and will expire 5 years from the grant date. During the year ended December 31, 2018, the Company recognized stock compensation costs of $656,735 related to the 250,000 options. On July 25, 2018, the Company entered into an agreement with a consultant to develop products based on certain intellectual property owned by the Company. In conjunction with the consulting agreement, the Company granted a stock option to the consultant to purchase a total of 50,000 shares of the common stock of the Company. 12,500 shares of the option with a fair value of $44,994 vested immediately, while the remaining 37,500 shares vest on completion of certain performance conditions to the reasonable satisfaction of the Company. Specifically, 25,000 shares vest upon completion of design and construction of the AcQviz TM TM As of December 31, 2018, options were valued based upon the Black-Scholes option-pricing model, with a stock price of $4.00, volatility of 115%, and an average risk-free rate of 2.46%. During the years ended December 31, 2018 and 2017, we recognized aggregate stock-compensation expense of $1,595,037 and $2,115,319, respectively, based upon stock prices ranging from $1.76 to $4.00 per share, of which $1,595,037 and $2,094,334 was recorded in general and administrative expense, $0 and $20,357 was recorded in sales and marketing expense, and $0 and $628 was recorded in research and development expense, respectively. As of December 31, 2018 , the Company had an aggregate of 100,000 remaining unvested options outstanding, with a total estimated fair value of $399,716, 2,368,750 .

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2018
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	11. Related Party Transactions On September 29, 2017, we completed the acquisition of substantially all of the assets and liabilities of VectorVision Ohio in exchange for 1,525,000 shares of our common stock, pursuant to the Asset Purchase Agreement, which was entered into on an arm’s-length basis. David W. Evans, our Director, owned 28% of the issued and outstanding shares of VectorVision Ohio and his wife, Tamara Evans, owned 72% of the issued and outstanding shares of VectorVision Ohio. VectorVision Ocular Health, Inc is a wholly owned subsidiary of the Company formed by the Company in connection with the acquisition of assets from VectorVision Ohio. Mr. Evans was appointed as a director of the Company on September 29, 2017 pursuant to the Asset Purchase Agreement. We entered into a Consulting Agreement with Dr. Evans, dated as of September 29, 2017 (the “Consulting Agreement”), whereby Dr. Evans has been engaged to serve as a consultant to the Company to further the Company’s planned development and commercialization of the Company’s portfolio of products and technology. The Consulting Agreement has an initial term of 3 years, with automatic one-year renewals unless earlier terminated. Dr. Evans is entitled to compensation of $10,000 per month. Due to and from related parties represents unreimbursed expenses and compensation incurred on behalf of, and amounts loaned to the Company by, Michael Favish, the Company’s Chief Executive Officer, as well as other shareholders. The advances are unsecured, non-interest bearing and are due on demand. As of December 31, 2018 and 2017, the Company had $0 and $146,133, respectively, due to related parties. During the twelve months ended December 31, 2018, the Company incurred and paid $275,000 of salary expense to our CEO, Michael Favish. During the twelve-month period ended December 31, 2017, the Company incurred salary expense of $250,000 and paid $170,000 in salary to Mr. Favish. Accrued amounts are included in general and administrative expenses.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	12. Income Taxes Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets as of December 31, 2018 and 2017 are summarized below. December 31, 2018 2017 Net operating loss carryforwards $ 2,689,000 $ 1,551,000 Stock-based compensation 942,000 504,000 Amortization of intangibles 19,000 — Accrued compensation — 17,000 Depreciation (1,000 ) 5,000 Total deferred tax assets 3,649,000 2,077,000 Valuation allowance (3,649,000 ) (2,077,000 ) Net deferred tax assets $ — $ — In assessing the potential realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the Company attaining future taxable income during the periods in which those temporary differences become deductible. As of December 31, 2018, management was unable to determine if it is more likely than not that the Company’s deferred tax assets will be realized and has therefore recorded an appropriate valuation allowance against deferred tax assets at such dates. No federal tax provision has been provided for the years ended December 31, 2018 and 2017, due to the losses incurred during the periods. Reconciled below is the difference between the income tax rate computed by applying the U.S. federal statutory rate and the effective tax rates for the years ended December 31, 2018 and 2017: Years Ended December 31, 2018 2017 U. S. federal statutory tax rate (21.0 )% (35.0 )% Non-deductible stock-based compensation — % 4.3 % Non-deductible fair value of warrant extensions 4.4 % — % Expirations related to stock-based compensation 0.1 % — % Adjustment to deferred tax asset 0.4 % 68.5 % Change in valuation allowance 16.0 % (38.0 )% Other 0.1 % 0.2 % Effective tax rate 0.0 % 0.0 % At December 31, 2018, the Company has available net operating loss carryforwards for federal income tax purposes of approximately $9,945,000 which, if not utilized earlier, will begin to expire in 2035. While the Company has not performed a formal analysis of the availability of its net operating loss carryforwards under Internal Revenue Code Sections 382 and 383, management expects that the Company’s ability to use its net operating loss carryforwards will be limited in future periods.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2018
Subsequent Events [Abstract]
Subsequent Events [Text Block]	13. Subsequent Events On January 30, 2019, Guardion Health Sciences, Inc. (the “Company”) filed with the Secretary of State of Delaware an amendment to the Company’s Certificate of Incorporation, (the “Charter Amendment”) to affect a reverse stock split whereby every two (2) shares of the Company’s common stock issued and outstanding immediately prior to filing the Charter Amendment (the “Old Common Stock”) were automatically, without further action on the part of the Company or any holder of Old Common Stock, reclassified, combined, converted and changed into one (1) fully paid and nonassessable share of common stock, par value of $0.001 per share (the “New Common Stock”). Holders who otherwise would have been entitled to receive fractional share interests of New Common Stock upon the effectiveness of the reverse stock split received one (1) whole share of New Common Stock in lieu of any fractional share created as a result of the reverse stock split. The reverse stock split was approved by the Company’s stockholders at the Company’s Annual Meeting of Stockholders held on November 20, 2018. On February 11, 2019, two investors exercised warrants for 312,500 shares of common stock. The warrants were exercisable for $0.50 per share, and the Company received $31,250 in cash. The Company will issue the shares and record the cash received as additional equity.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates Our financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The preparation of our financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the financial statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions used in valuing assets acquired in business acquisitions, impairment testing of long-term assets, accruals for potential liabilities, valuing equity instruments issued during the period, and realization of deferred tax assets. Actual results could differ from those estimates. Certain prior period amounts have been reclassified to conform to current period presentation. Such amounts consist of operating segment disclosures, whereby revenue and cost of goods sold have been broken out on the Consolidated Statements of Operations to conform with the Company’s two reportable business segments as of December 31, 2018.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as noted below. Disclosure as to transfers into and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required. Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives. Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges. Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded, non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models. The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end. The Company believes the carrying amount of its financial instruments (consisting of cash, accounts receivable, and accounts payable and accrued liabilities) approximates fair value due to the short-term nature of such instruments. The fair value of the Company’s line of credit approximates its carrying value given the interest rate of such line of credit.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk and Other Risks and Uncertainties Cash balances are maintained at large, well-established financial institutions. At times, cash balances may exceed federally insured limits. Insurance coverage limits are $250,000 per depositor at each financial institution. The Company has never experienced any losses related to these balances. During the year ended December 31, 2018, the Vision Testing Diagnostics segment had one customer who accounted for approximately 47% 30% of the Company's sales. No other customer accounted for more than 10% of sales in either year.
Accounts Receivable, Policy [Policy Text Block]	Accounts Receivable The Company evaluates the collectability of its trade accounts receivable based on multiple factors. In circumstances where the Company becomes aware of a specific customer’s inability to meet its financial obligations to the Company, a specific reserve for bad debts is estimated and recorded, which reduces the recognized receivable to the estimated amount the Company believes will ultimately be collected. In addition to specific customer identification of potential bad debts, bad debt charges are recorded based on the Company’s historical losses and an overall assessment of past due trade accounts receivable outstanding. The allowance for doubtful accounts and returns is established through a provision reducing the carrying value of receivables. At December 31, 2018 and 2017, no allowance for doubtful accounts and returns was considered necessary.
Inventory, Policy [Policy Text Block]	Inventories The Company’s inventories are stated at the lower of weighted-average cost or market. The cost of finished goods and raw materials is determined on a first-in, first-out basis. The Company evaluates its inventories for obsolescence and recoverability at each reporting period.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are initially recorded at their historical cost. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from three to seven years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term. Management assesses the carrying value of property and equipment whenever events or changes in circumstances indicate that the carrying value may not be recoverable. If there is indication of impairment, management prepares an estimate of future cash flows expected to result from the use of the asset and its eventual disposition. If these cash flows are less than the carrying amount of the asset, an impairment loss is recognized to write down the asset to its estimated fair value. As of December 31, 2018 and 2017, the Company was not aware of the existence of any indicators of impairment at such dates.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Intangible Assets In connection with the VectorVision transaction, the Company identified and allocated estimated fair values to intangible assets including goodwill and customer relationships. In accordance with Accounting Standard Codification (“ASC”) 350 – Intangibles – Goodwill and Other, the Company determined whether these assets are expected to have indefinite (such as goodwill) or limited useful lives, and for those with limited lives, the Company established an amortization period and method of amortization. Its goodwill and other intangible assets are subject to periodic impairment testing. The Company utilized the services of an independent third-party valuation firm to assist in identifying intangible assets and in estimating their fair values. The useful lives for the Company’s intangible assets other than goodwill were estimated based on Management’s consideration of various factors, including assumptions that market participants might use about sales expectations as well as potential effects of obsolescence, competition, technological progress and the regulatory environment. Because the future pattern in which the economic benefits of these intangible assets may not be reliably determined, amortization expense is generally calculated on a straight-line basis. Amortization expense for the identifiable intangible assets associated with the VectorVision acquisition is approximately $54,000 per quarter and is included with general and administrative expenses in the Company’s Statements of Operations. The Company reviews all intangible assets for impairment when circumstances indicate that their carrying values may not be recoverable. If the carrying value of an asset group is not recoverable, the Company recognizes an impairment loss for the excess carrying value over the fair value in its consolidated statements of operations. As of December 31, 2018 and 2017, the Company was not aware of the existence of any indicators of impairment of its intangibles at such dates.
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill Goodwill represents the excess of the purchase consideration over the fair value of the net tangible and identifiable intangible assets acquired in a business combination. The Company evaluates goodwill for impairment on an annual basis or whenever events and changes in circumstances suggest that the carrying amount may not be recoverable. The Company conducts its annual impairment analysis in the beginning of the fourth quarter of each fiscal year. Impairment of goodwill is tested at the reporting unit level by comparing the reporting unit’s carrying amount, including goodwill, to the fair value of the reporting unit. Estimations and assumptions regarding the number of reporting units, future performances, results of the Company’s operations and comparability of its market capitalization and net book value will be used. If the carrying amount of the reporting unit exceeds its fair value, goodwill is considered impaired and an impairment loss is measured by the resulting amount. Because the Company has one reporting unit, the Company utilizes an entity-wide approach to assess goodwill for impairment. As of December 31, 2018 and 2017, the Company was not aware of the existence of any indicators of impairment of its goodwill at such dates.
Deferred Charges, Policy [Policy Text Block]	Deferred Offering Costs Deferred offering costs consist principally of legal, accounting, and underwriters’ fees incurred related to the planned underwritten public offering of the Company’s Common Stock. These deferred offering costs will be charged against the gross proceeds received or will be charged to expense if the offering is not completed.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company’s revenue is comprised of sales of medical foods and dietary supplements to consumers through a direct sales/credit card process. In addition, the Company sells medical device equipment and supplies to customers both in the U.S. and internationally. Through December 31, 2017, the Company recognized revenue when risk of loss transferred to its customers and collection of the receivable was reasonably assured, which generally occurred when the product was shipped. A product is not shipped without an order from the customer and credit acceptance procedures performed. The Company allows for returns within 30 days of purchase, although for all periods presented, returns have been insignificant. On January 1, 2018. the Company adopted ASU 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09” or “Topic 606”) and all related amendments and applied the concepts to all contracts using the full retrospective method. The new standard provides authoritative guidance clarifying the principles for recognizing revenue and developing a common revenue standard for U.S. generally accepted accounting principles. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods and services to customers in an amount that reflects the consideration to which the entity expects to be entitled in the exchange for those goods or services. Under the new guidance, revenue is recognized when control of promised goods or services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company reviews its sales transactions to identify contractual rights, performance obligations, and transaction prices, including the allocation of prices to separate performance obligations, if applicable. Revenue and costs of sales are recognized once products are delivered to the customer’s control and performance obligations are satisfied. Due to the nature of the products sold by the Company, the adoption of the new standard has had no quantitative effect on the financial statements and the Company had no cumulative impact of adopting Topic 606 to record through accumulated deficit. However, the guidance requires additional disclosures to help readers of financial statements better understand the nature, amount, timing, and uncertainty of revenue that is recognized. All products sold by the Company are distinct individual products and consist of medical foods, supplemental formulas, medical devices and related supplies. The products are offered for sale as finished goods only, and there are no performance obligations required post-shipment for customers to derive the expected value from them. Contracts with customers contain no incentives or discounts that could cause revenue to be allocated or adjusted over time. Control of products sold transfers to customers upon shipment from the Company’s facilities, and the Company’s performance obligations are satisfied at that time. Shipping and handling activities are performed before the customer obtains control of the goods and therefore represent a fulfillment activity rather than a promised service to the customer. Payment for sales of Lumega-Z is generally made by approved credit cards. Payments for medical device sales are generally made by check, credit card, or wire transfer. Historically the Company has not experienced any significant payment delays from customers. The Company provides a 30-day right of return to its retail Lumega-Z customers. A right of return does not represent a separate performance obligation, but because customers are allowed to return products, the consideration to which the Company expects to be entitled is variable. Upon evaluation of historical Lumega-Z and VectorVision product returns, the Company determined that less than one percent of products is returned, and therefore believes it is probable that such returns will not cause a significant reversal of revenue in the future. Due to the insignificant amount of historical returns as well as the standalone nature of the Company’s products and assessment of performance obligations and transaction pricing for the Company’s sales contracts, the Company does not currently maintain a contract asset or liability balance at this time. The Company assesses its contracts and the reasonableness of its conclusions on a quarterly basis. The following table presents the Company’s revenues disaggregated by segment: Year Ended December 31, 2018 2017 Medical foods $ 332,795 $ 245,217 Vision testing diagnostics 609,358 192,132 $ 942,153 $ 437,349
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s medical foods and related products. Research and development expenditures, which include stock compensation expense, are expensed as incurred and totaled $231,847 and $259,463 for the years ended December 31, 2018 and 2017, respectively.
Patent Costs Policy [Policy Text Block]	Patent Costs The Company is the owner of three issued domestic patents, two pending domestic patent applications, one issued foreign patent in Europe, and three foreign patent applications in Canada, Europe and Hong Kong. Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and any related patent applications, patent costs, including patent-related legal fees, filing fees and internally generated costs, are expensed as incurred. During the years ended December 31, 2018 and 2017, patent costs were $93,149 and $30,789, respectively, and are included in general and administrative costs in the statements of operations.
Compensation Related Costs, Policy [Policy Text Block]	Stock-Based Compensation The Company periodically issues stock-based compensation to officers, directors, contractors and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date. Stock-based payments to officers, directors, consultants, contractors, and employees, which include grants of employee stock options, are recognized in the financial statements based on their fair values. Stock option grants, which are generally time vested, will be measured at the grant date fair value and charged to operations on a straight-line basis over the vesting period. The fair value of stock options is determined utilizing the Black-Scholes option-pricing model, which is affected by several variables, including the risk-free interest rate, the expected dividend yield, the expected life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date and the estimated volatility of the common stock over the term of the equity award. The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance of the FASB whereby the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period using a graded vesting basis. In certain circumstances where there are no future performance requirements by the non-employee, grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date. The Company recognizes stock compensation expense, on stock purchases at a price less than fair value, and for fully-vested stock issued to consultants and other service providers, for the excess of fair value of the stock over the price paid for the stock. The Company recognizes the fair value of stock-based compensation within its statements of operations with classification depending on the nature of the services rendered. The Company will issue new shares to satisfy stock option exercises.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company currently accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities. The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company determines that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made. The Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company’s net operating losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which the Company currently operates or has operated in the past. The Company had no unrecognized tax benefits as of December 31, 2018 and 2017 and does not anticipate any material amount of unrecognized tax benefits within the next 12 months. The Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The tax effects of a position are recognized only if it is “more-likely-than-not” to be sustained by the taxing authority as of the reporting date. If the tax position is not considered “more-likely-than-not” to be sustained, then no benefits of the position are recognized. As of December 31, 2018, the Company had not recorded any liability for uncertain tax positions. In subsequent periods, any interest and penalties related to uncertain tax positions will be recognized as a component of income tax expense. On December 22, 2017, the President of the United States signed and enacted into law H.R. 1 (the “Tax Reform Law”). The Tax Reform Law, effective for tax years beginning on or after January 1, 2018, except for certain provisions, resulted in significant changes to existing United States tax law, including various provisions that will impact the Company. The Tax Reform Law reduces the federal corporate tax rate from 35% to 21% effective January 1, 2018. The Company will continue to analyze the provisions of the Tax Reform Law to assess the impact to the Company’s consolidated financial statements.
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share The Company’s computation of basic and diluted net loss per common share is measured as net loss divided by the weighted average common shares outstanding during the respective periods, excluding unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Potential common shares such as from unexercised warrants, options, and shares associated with convertible debt outstanding that have an anti-dilutive effect are excluded from the calculation of diluted net loss per share. The Company’s basic and diluted net loss per share is the same for all periods presented because all shares issuable upon exercise of warrants and conversion of convertible debt outstanding are anti-dilutive as they decrease loss per share. The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive: December 31, 2018 2017 Warrants 1,230,674 1,491,833 Options 1,362,500 1,062,500 2,593,174 2,554,333
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In February 2016, the FASB issued Accounting Standards Update No. 2016-02 (ASU 2016-02), Leases (Topic 842). ASU 2016-02 requires a lessee to record a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, on the balance sheet for all leases with terms longer than 12 months, as well as the disclosure of key information about leasing arrangements. ASU 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. ASU 2016-02 requires classification of all cash payments within operating activities in the statement of cash flows. Disclosures are required to provide the amount, timing and uncertainty of cash flows arising from leases. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. ASU 2016-02 has subsequently been amended and modified by ASU 2018-10 (codification improvements), 2018-11 (implementation improvements) and 2018-20 (scope revisions). ASU 2016-02 (including the subsequent amendments and modifications) is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. The Company is evaluating the impact of the adoption of ASU 2016-02 on the Company’s financial statement presentation and disclosures and expects the most significant change will be the recognition of right-to-use assets and lease liabilities on its balance sheet for real estate operating lease commitments. In July 2017, the FASB issued Accounting Standards Update No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features; (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception (“ASU 2017-11”). ASU 2017-11 allows companies to exclude a down round feature when determining whether a financial instrument (or embedded conversion feature) is considered indexed to the entity’s own stock. As a result, financial instruments (or embedded conversion features) with down round features may no longer be required to be accounted for as derivative liabilities. A company will recognize the value of a down round feature only when it is triggered and the strike price has been adjusted downward. For equity-classified freestanding financial instruments, an entity will treat the value of the effect of the down round as a dividend and a reduction of income available to common shareholders in computing basic earnings per share. For convertible instruments with embedded conversion features containing down round provisions, entities will recognize the value of the down round as a beneficial conversion discount to be amortized to earnings. ASU 2017-11 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The guidance in ASU 2017-11 is to be applied using a full or modified retrospective approach. The adoption of ASU 2017-11 is not currently expected to have any impact on the Company’s financial statement presentation or disclosures. In June 2018, the FASB issued Accounting Standards Update 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”). ASU 2018-07 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. ASU 2018-07 also clarifies that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Revenue from Contracts with Customers (Topic 606). ASU 2018-07 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company will adopt the provisions of ASU 2018-07 in the quarter beginning January 1, 2019. The adoption of ASU 2018-07 is not expected to have a material impact on the Company’s financial statement presentation or disclosures. The Company’s management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Disaggregation of Revenue [Table Text Block]	The following table presents the Company’s revenues disaggregated by segment: Year Ended December 31, 2018 2017 Medical foods $ 332,795 $ 245,217 Vision testing diagnostics 609,358 192,132 $ 942,153 $ 437,349
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive: December 31, 2018 2017 Warrants 1,230,674 1,491,833 Options 1,362,500 1,062,500 2,593,174 2,554,333

Segment Reporting (Tables)

Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2018
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	The following tables set forth our results of operations by segment (expenses allocated to Corporate consist of non-cash stock compensation expense, depreciation and amortization, and corporate legal fees): For the Year Ended December 31, 2018 Corporate Medical Foods Vision Testing Diagnostics Total Revenue $ - $ 332,795 $ 609,358 $ 942,153 Cost of goods sold - 161,023 237,156 398,179 Gross profit - 171,772 372,202 543,974 Operating expenses 2,707,924 3,566,835 412,936 6,687,695 Loss from operations $ (2,707,924 ) $ (3,395,063 ) $ (40,734 ) $ (6,143,721 ) For the Year Ended December 31, 2017 Corporate Medical Foods Vision Testing Diagnostics Total Revenue $ - $ 245,217 $ 192,132 $ 437,349 Cost of goods sold - 110,993 64,477 175,470 Gross profit - 134,224 127,655 261,879 Operating expenses 2,865,513 2,595,776 82,032 5,543,321 Loss from operations $ (2,865,513 ) $ (2,461,552 ) $ 45,623 $ (5,281,442 )
Schedule Of Segment Reporting Information By Assets [Table Text Block]	The following tables set forth our total assets by segment. Intersegment balances and transactions have been removed: As of December 31, 2018 Corporate Medical Foods Vision Testing Diagnostics Total Current assets Cash $ - $ 552,613 $ 118,335 $ 670,948 Inventories - 235,957 122,040 357,957 Other - 44,110 31,866 75,976 Total current assets - 832,680 272,241 1,104,921 Property and equipment, net - 264,178 10,626 274,804 Deferred offering 270,000 - - 270,000 Intangible assets, net 456,104 - - 456,104 Goodwill 1,563,520 - - 1,563,520 Other - 11,751 - 11,751 Total assets $ 2,289,624 $ 1,108,609 $ 282,867 $ 3,681,100 As of December 31, 2017 Corporate Medical Foods Vision Testing Diagnostics Total Current assets Cash $ - $ 4,709,512 $ 25,718 $ 4,735,230 Inventories - 57,978 96,752 154,730 Other - 119,640 70,295 189,935 Total current assets - 4,887,130 192,765 5,079,895 Property and equipment, net - 86,723 8,874 95,597 Deferred offering - - - - Intangible assets, net 620,741 - - 620,741 Goodwill 1,563,520 - - 1,563,520 Other - 10,470 - 10,470 Total assets $ 2,184,261 $ 4,984,323 $ 201,639 $ 7,370,223

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2018
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventories consisted of the following: December 31, 2018 2017 Raw materials $ 282,574 $ 133,354 Finished goods 75,423 21,376 $ 357,997 $ 154,730

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment consisted of the following: December 31, 2018 2017 Leasehold improvements $ 98,357 $ 98,357 Testing equipment 249,447 150,603 Furniture and fixtures 163,186 50,300 Computer equipment 64,976 16,464 Office equipment 8,193 8,193 584,159 323,917 Less accumulated depreciation and amortization (309,355 ) (228,320 ) $ 274,804 $ 95,597

Acquisition of VectorVision (Ta

Acquisition of VectorVision (Tables)	12 Months Ended
	Dec. 31, 2018
Business Combinations [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	The following table summarizes the allocation of preliminary fair values of the purchase consideration to the assets and liabilities assumed: Fair Values Common stock consideration $ 2,287,500 Liabilities assumed 108,722 Total purchase consideration 2,396,222 Cash (4,895 ) Accounts receivable (50,105 ) Inventory (93,293 ) Prepaid assets (551 ) Property and equipment (9,458 ) Intangible assets (674,400 ) Goodwill $ 1,563,520
Business Acquisition, Pro Forma Information [Table Text Block]	The following unaudited pro forma financial information gives effect to the Company’s acquisition of VectorVision as if the acquisition had occurred on January 1, 2017 and had been included in the Company’s consolidated statements of operations during the year ended December 31, 2017: December 31, 2017 Pro forma net revenues $ 824,028 Pro forma operating expenses $ 6,087,726 Pro forma net loss attributable to common shareholders $ (6,500,590 ) Pro forma net loss per share $ (0.47 )

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	The Company’s finite-lived intangible assets consisted of the following: December 31, 2018 2017 Customer relationships $ 430,700 $ 430,700 Technology 161,100 161,100 Trade Names 65,600 65,600 Noncompetition 17,000 17,000 674,400 674,400 Less accumulated depreciation and amortization (268,296 ) (53,659 ) $ 406,104 $ 620,741
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	The Company estimates future amortization expense on its finite-lived intangible assets as of December 31, 2018 to be as follows: For Years Ended December 31, 2019 $ 214,637 2020 165,320 2021 16,307 2022 9,840 $ 406,104

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	The approximate future minimum lease payments under non-cancelable operating leases at December 31, 2018 are as follows: Years ending December 31, 2019 $ 166,770 2020 171,767 2021 176,933 2022 182,249 2023 and thereafter 98,417 $ 796,136

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) (Tables)	12 Months Ended
	Dec. 31, 2018
Stockholders' Equity Note [Abstract]
Nonvested Restricted Stock Shares Activity [Table Text Block]	Additional details of the Company’s restricted common stock are as follows: Number of Shares Fair Value Weighted Average Grant Date Fair Value Per Share Non-vested, December 31, 2016 176,250 $ 113,754 $ 2.26 Issued 81,250 143,000 1.76 Vested (257,500 ) (256,754 ) 2.10 Forfeited - - - Non-vested, December 31, 2017 - $ - $ -
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	A summary of the Company’s warrant activity is as follows: Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) December 31, 2016 1,461,836 $ 0.88 2.19 Granted 30,000 0.03 0.04 Forfeitures - - - Expirations - - - Exercised - - - December 31, 2017 1,491,836 0.89 1.16 Granted - - - Forfeitures - - - Expirations (158,162 ) 0.17 - Exercised (103,000 ) 0.01 - December 31, 2018, all exercisable 1,230,674 $ 0.71 0.29
Exercise Price Of Warrants Outstanding And Exercisable Table Text Block	The exercise prices of warrants outstanding and exercisable as of December 31, 2018 are as follows: Warrants Outstanding and Exercisable (Shares) Exercise Prices 876,250 $ 0.50 70,000 1.00 30,000 1.50 254,424 2.00 1,230,674
Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the Company’s stock option activity is as follows: Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) December 31, 2016 - - - Granted 1,062,500 $ 2.19 5.14 Forfeitures - - - Expirations - - - Exercised - - - December 31, 2017 1,062,500 2.19 5.14 Granted 300,000 0.55 0.55 Forfeitures - - - Expirations - - - Exercised - - - December 31, 2018, outstanding 1,362,500 $ 2.26 3.78 December 31, 2018, exercisable 1,262,500 $ 2.26 3.78
Exercise Price Of Options Outstanding And Exercisable Table Text Block	The exercise prices of options outstanding and exercisable as of December 31, 2018 are as follows: Options Outstanding (Shares) Options Exercisable (Shares) Exercise Prices 625,000 625,000 $ 2.00 62,500 62,500 2.30 675,000 575,000 2.50 1,362,500 1,262,500

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Significant components of the Company’s deferred tax assets as of December 31, 2018 and 2017 are summarized below. December 31, 2018 2017 Net operating loss carryforwards $ 2,689,000 $ 1,551,000 Stock-based compensation 942,000 504,000 Amortization of intangibles 19,000 — Accrued compensation — 17,000 Depreciation (1,000 ) 5,000 Total deferred tax assets 3,649,000 2,077,000 Valuation allowance (3,649,000 ) (2,077,000 ) Net deferred tax assets $ — $ —
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Reconciled below is the difference between the income tax rate computed by applying the U.S. federal statutory rate and the effective tax rates for the years ended December 31, 2018 and 2017: Years Ended December 31, 2018 2017 U. S. federal statutory tax rate (21.0 )% (35.0 )% Non-deductible stock-based compensation — % 4.3 % Non-deductible fair value of warrant extensions 4.4 % — % Expirations related to stock-based compensation 0.1 % — % Adjustment to deferred tax asset 0.4 % 68.5 % Change in valuation allowance 16.0 % (38.0 )% Other 0.1 % 0.2 % Effective tax rate 0.0 % 0.0 %

Organization and Business Ope_2

Organization and Business Operations (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Jan. 30, 2019
Net Cash Provided by (Used in) Operating Activities	$ (4,173,831)	$ (3,403,696)
Net Income (Loss) Attributable to Parent, Total	$ (7,767,407)	$ (5,305,169)
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Retained Earnings (Accumulated Deficit)	$ (34,633,363)	$ (26,865,956)
Subsequent Event [Member]
Common Stock, Par or Stated Value Per Share			$ 0.001

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenues	$ 942,153	$ 437,349
Medical Foods [Member]
Revenues	332,795	245,217
Vision Testing Diagnotics [Member]
Revenues	$ 609,358	$ 192,132

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details 1) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,593,174	2,554,333
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,362,500	1,062,500
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,230,674	1,491,833

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Research and Development Expense	$ 231,847	$ 259,463
Amortization of Intangible Assets	54,000	$ 53,659
Insurance Coverage Limits	$ 250,000
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%	35.00%
Scenario, Plan [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%
Sales Revenue, Net [Member] | Customer Concentration Risk [Member]
Concentration Risk, Percentage	47.00%	30.00%
Sales Revenue, Net [Member] | Customer One Concentration Risk [Member]
Concentration Risk, Percentage	10.00%
Patents [Member]
Research and Development Expense	$ 93,149	$ 30,789

Segment Reporting (Details)

Segment Reporting (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenue	$ 942,153	$ 437,349
Cost of goods sold	398,179	175,470
Gross profit	543,974	261,879
Operating expenses	6,687,695	5,543,321
Loss from operations	(6,143,721)	(5,281,442)
Corporate [Member]
Revenue	0	0
Cost of goods sold	0	0
Gross profit	0	0
Operating expenses	2,707,924	2,865,513
Loss from operations	(2,707,924)	(2,865,513)
Medical Foods [Member]
Revenue	332,795	245,217
Cost of goods sold	161,023	110,993
Gross profit	171,772	134,224
Operating expenses	3,566,835	2,595,776
Loss from operations	(3,395,063)	(2,461,552)
Vision Testing Diagnostics [Member]
Revenue	609,358	192,132
Cost of goods sold	237,156	64,477
Gross profit	372,202	127,655
Operating expenses	412,936	82,032
Loss from operations	$ (40,734)	$ 45,623

Segment Reporting (Details 1)

Segment Reporting (Details 1) - USD ($)	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Current assets
Cash	$ 670,948	$ 4,735,230	$ 62,520
Inventories	357,997	154,730
Other	75,976	189,935
Total current assets	1,104,921	5,079,895
Property and equipment, net	274,804	95,597
Deferred offering	270,000	0
Intangible assets, net	456,104	620,741
Goodwill	1,563,520	1,563,520
Other	11,751	10,470
Total assets	3,681,100	7,370,223
Corporate [Member]
Current assets
Cash	0	0
Inventories	0	0
Other	0	0
Total current assets	0	0
Property and equipment, net	0	0
Deferred offering	270,000	0
Intangible assets, net	456,104	620,741
Goodwill	1,563,520	1,563,520
Other	0	0
Total assets	2,289,624	2,184,261
Medical Foods [Member]
Current assets
Cash	552,613	4,709,512
Inventories	235,957	57,978
Other	44,110	119,640
Total current assets	832,680	4,887,130
Property and equipment, net	264,178	86,723
Deferred offering	0	0
Intangible assets, net	0	0
Goodwill	0	0
Other	11,751	10,470
Total assets	1,108,609	4,984,323
Vision Testing Diagnostics [Member]
Current assets
Cash	118,335	25,718
Inventories	122,040	96,752
Other	31,866	70,295
Total current assets	272,241	192,765
Property and equipment, net	10,626	8,874
Deferred offering	0	0
Intangible assets, net	0	0
Goodwill	0	0
Other	0	0
Total assets	$ 282,867	$ 201,639

Inventories (Details)

Inventories (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Raw materials	$ 282,574	$ 133,354
Finished goods	75,423	21,376
Inventory, Net	$ 357,997	$ 154,730

Property and Equipment, net (De

Property and Equipment, net (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment, Gross, Total	$ 584,159	$ 323,917
Less accumulated depreciation and amortization	(309,355)	(228,320)
Property, Plant and Equipment, Net, Total	274,804	95,597
Leasehold Improvements [Member]
Property, Plant and Equipment, Gross, Total	98,357	98,357
Testing equipment [Member]
Property, Plant and Equipment, Gross, Total	249,447	150,603
Furniture and Fixtures [Member]
Property, Plant and Equipment, Gross, Total	163,186	50,300
Computer Equipment [Member]
Property, Plant and Equipment, Gross, Total	64,976	16,464
Office Equipment [Member]
Property, Plant and Equipment, Gross, Total	$ 8,193	$ 8,193

Property and Equipment, net (_2

Property and Equipment, net (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Depreciation, Depletion and Amortization, Nonproduction, Total	$ 295,672	$ 118,821
Research and Development Expense	231,847	259,463
General and Administrative Expense, Total	4,934,986	4,683,932
Selling and Marketing Expense, Total	1,520,862	599,926
Property, Plant and Equipment [Member]
Depreciation, Depletion and Amortization, Nonproduction, Total	81,035	65,161
Research and Development Expense	34,524	29,574
General and Administrative Expense, Total	35,613	35,587
Selling and Marketing Expense, Total	$ 10,898	$ 0

Acquisition of VectorVision (De

Acquisition of VectorVision (Details) - USD ($)	1 Months Ended	9 Months Ended
	Sep. 29, 2017	Sep. 29, 2017	Dec. 31, 2018	Dec. 31, 2017
Goodwill			$ 1,563,520	$ 1,563,520
VectorVision Inc [Member]
Common stock consideration	$ 2,287,500	$ 2,287,500
Liabilities assumed		108,722
Total purchase consideration		2,396,222
Cash	(4,895)	(4,895)
Accounts receivable	(50,105)	(50,105)
Inventory	(93,293)	(93,293)
Prepaid assets	(551)	(551)
Property and equipment	(9,458)	(9,458)
Intangible assets	(674,400)	(674,400)
Goodwill	$ 1,563,520	$ 1,563,520

Acquisition of VectorVision (_2

Acquisition of VectorVision (Details 1)	12 Months Ended
	Dec. 31, 2017USD ($)$ / shares
Pro forma net revenues	$ 824,028
Pro forma operating expenses	6,087,726
Pro forma net loss attributable to common shareholders	$ (6,500,590)
Pro forma net loss per share | $ / shares	$ (0.47)

Acquisition of VectorVision (_3

Acquisition of VectorVision (Details Textual)	1 Months Ended	9 Months Ended
	Sep. 29, 2017USD ($)shares	Sep. 29, 2017USD ($)
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | shares	1,525,000
Equity Method Investment, Ownership Percentage	11.00%	11.00%
VectorVision Inc [Member]
Business Acquisition, Equity Interest Issued or Issuable, Description	With respect to the 1,525,000 shares of common stock, 125,000 shares were held back as security for VectorVision’s indemnification obligations to the Company and the remaining 1,400,000 shares were issued to VectorVision at the closing of the transaction.
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable | $	$ 2,287,500	$ 2,287,500

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets, Gross	$ 674,400	$ 674,400
Less accumulated depreciation and amortization	(268,296)	(53,659)
Finite-Lived Intangible Assets, Net	406,104	620,741
Customer relationships [Member]
Finite-Lived Intangible Assets, Gross	430,700	430,700
Technology [Member]
Finite-Lived Intangible Assets, Gross	161,100	161,100
Trade Names [Member]
Finite-Lived Intangible Assets, Gross	65,600	65,600
Noncompetition [Member]
Finite-Lived Intangible Assets, Gross	$ 17,000	$ 17,000

Intangible Assets (Details 1)

Intangible Assets (Details 1) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
2,019	$ 214,637
2,020	165,320
2,021	16,307
2,022	9,840
Finite-Lived Intangible Assets, Net	$ 406,104	$ 620,741

Intangible Assets (Details Text

Intangible Assets (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Amortization of Intangible Assets	$ 54,000	$ 53,659

Acquisition of Intellectual P_2

Acquisition of Intellectual Property (Details Textual) - USD ($)	Nov. 03, 2017	Jan. 26, 2018	Dec. 31, 2018	Dec. 31, 2017
Payments to Acquire Intangible Assets			$ 50,000	$ 0
Stock Issued During Period, Shares, Issued for Services	2,173,914
Intellectual Property [Member]
Stock Issued During Period, Shares, Issued for Services		250,000

Commitments and Contingencies_2

Commitments and Contingencies (Details)	Dec. 31, 2018USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,019	$ 166,770
2,020	171,767
2,021	176,933
2,022	182,249
2023 and thereafter	98,417
Operating Leases, Future Minimum Payments Due, Total	$ 796,136

Commitments and Contingencies_3

Commitments and Contingencies (Details Textual)	12 Months Ended
	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Sep. 29, 2017USD ($)a	Oct. 31, 2012a
Average Monthly Lease Payments	$ 12,816		$ 1,825
Deposit Paid for Lease	47,449
Deposit Paid for Prepaid Rent	36,979
Deposit On Lease Agreement	10,470
Operating Leases, Rent Expense	$ 192,624	$ 157,751
Area of Land | a			5,000	9,605
Lessee Operating Lease Renewal Term	5 years		65 months
Loss Contingency, Damages Sought, Value	$ 192,000
Accrued Rent	$ 3,712	$ 3,712

Stockholders' Equity (Deficit_2

Stockholders' Equity (Deficit) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2016
Number of Shares, Beginning Balance			176,250
Number of Shares, Issued	81,250
Number of Shares, Vested	(257,500)
Number of Shares, Forfeited	0
Number of Shares, Ending Balance			176,250
Fair Value, Beginning Balance			$ 113,754
Fair Value, Issued	$ 143,000
Fair Value, Vested	(256,754)
Fair Value, Forfeited	$ 0
Fair Value, Ending Balance			$ 113,754
Weighted Average Grant Date Fair Value Per Share, Beginning Balance			$ 2.26
Weighted Average Grant Date Fair Value Per Share, Issued	$ 1.76
Weighted Average Grant Date Fair Value Per Share, Vested	2.10
Weighted Average Grant Date Fair Value Per Share, Forfeited	$ 0
Weighted Average Grant Date Fair Value Per Share, Ending Balance			$ 2.26
Restricted Stock [Member]
Number of Shares, Beginning Balance		0
Number of Shares, Issued	81,250
Number of Shares, Ending Balance		0
Fair Value, Beginning Balance		$ 0
Fair Value, Vested	$ (256,754)
Fair Value, Ending Balance		$ 0
Weighted Average Grant Date Fair Value Per Share, Beginning Balance		$ 0
Weighted Average Grant Date Fair Value Per Share, Ending Balance		$ 0

Stockholders' Equity (Deficit_3

Stockholders' Equity (Deficit) (Details 1) - $ / shares	1 Months Ended	12 Months Ended
	Nov. 30, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2018	Sep. 21, 2018	Jan. 31, 2018
Class of Warrant or Right [Line Items]
Shares, Granted	62,500	250,000
Ending Balance		1,362,500
December 31, 2018, all exercisable					1,262,500
Ending Balance		$ 0.50
December 31, 2018, all exercisable		$ 0.50			$ 0.50	$ 0.50	$ 0.02
Warrant [Member]
Class of Warrant or Right [Line Items]
Beginning Balance		1,491,836	1,461,836
Shares, Granted		0	30,000
Shares, Forfeitures		0	0
Shares, Expirations		(158,162)	0
Shares, Exercised		(103,000)	0
Ending Balance			1,491,836	1,461,836
December 31, 2018, all exercisable					1,230,674
Beginning Balance		$ 0.89	$ 0.88
Weighted Average Exercise Price, Granted		0	0.03
Weighted Average Exercise Price, Forfeitures		0	0
Weighted Average Exercise Price, Expirations		0.17	0
Weighted Average Exercise Price, Exercised		0.01	0
Ending Balance		$ 0.71	$ 0.89	$ 0.88
December 31, 2018, all exercisable		$ 0.89	$ 0.88	$ 0.88	$ 0.71
Beginning Balance		3 months 14 days	1 year 1 month 28 days	2 years 2 months 8 days
Weighted Average Remaining Contractual Term (Years), Granted			14 days
December 31, 2018, all exercisable		3 months 14 days	1 year 1 month 28 days	2 years 2 months 8 days
stock option [Member]
Class of Warrant or Right [Line Items]
Beginning Balance		1,062,500	0
Shares, Granted		300,000	1,062,500
Shares, Forfeitures		0	0
Shares, Expirations		0	0
Shares, Exercised		0	0
Ending Balance		1,362,500	1,062,500	0
December 31, 2018, all exercisable					1,262,500
Beginning Balance		$ 2.19	$ 0
Weighted Average Exercise Price, Granted		0.55	2.19
Weighted Average Exercise Price, Forfeitures		0	0
Weighted Average Exercise Price, Expirations		0	0
Weighted Average Exercise Price, Exercised		0	0
Ending Balance		$ 2.26	$ 2.19	$ 0
December 31, 2018, all exercisable		$ 2.19	$ 0	$ 0	$ 2.26
Beginning Balance		3 years 9 months 11 days	5 years 1 month 20 days
Weighted Average Remaining Contractual Term (Years), Granted		6 months 18 days	5 years 1 month 20 days
December 31, 2018, all exercisable		3 years 9 months 11 days	5 years 1 month 20 days

Stockholders' Equity (Deficit_4

Stockholders' Equity (Deficit) (Details 2) - $ / shares	12 Months Ended
	Dec. 31, 2018	Sep. 21, 2018	Jan. 31, 2018
Warrants Outstanding and Exercisable (Shares)	1,230,674
Exercise Prices	$ 0.50	$ 0.50	$ 0.02
Warrant one [Member]
Warrants Outstanding and Exercisable (Shares)	876,250
Exercise Prices	$ 0.50
Warrant Two [Member]
Warrants Outstanding and Exercisable (Shares)	70,000
Exercise Prices	$ 1
Warrant Three [Member]
Warrants Outstanding and Exercisable (Shares)	30,000
Exercise Prices	$ 1.50
Warrant Four [Member]
Warrants Outstanding and Exercisable (Shares)	254,424
Exercise Prices	$ 2

Stockholders' Equity (Deficit_5

Stockholders' Equity (Deficit) (Details 3) - $ / shares	Dec. 31, 2018	Nov. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	1,362,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	1,262,500
Share Price	$ 4	$ 2.30
Option EXercise Prices One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	625,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	625,000
Share Price	$ 2
Option EXercise Prices Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	62,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	62,500
Share Price	$ 2.30
Option EXercise Prices Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	675,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	575,000
Share Price	$ 2.50

Stockholders' Equity (Deficit_6

Stockholders' Equity (Deficit) (Details Textual)	Nov. 03, 2017USD ($)$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares	Jul. 25, 2018USD ($)shares	May 31, 2018$ / sharesshares	Apr. 30, 2018$ / sharesshares	Jan. 31, 2018USD ($)$ / sharesshares	Jan. 26, 2018USD ($)$ / sharesshares	Dec. 30, 2017USD ($)$ / sharesshares	Nov. 30, 2017USD ($)$ / sharesshares	Sep. 30, 2017USD ($)$ / sharesshares	Jun. 01, 2018$ / shares	Dec. 31, 2018USD ($)$ / sharesshares	Sep. 30, 2017USD ($)$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares	Sep. 21, 2018$ / sharesshares	Apr. 26, 2018shares
Class of Warrant or Right [Line Items]
Common Stock, Par or Stated Value Per Share | $ / shares		$ 0.001										$ 0.001		$ 0.001	$ 0.001
Share-based Compensation | $														$ 1,595,037	$ 1,932,268
Stock Issued During Period, Shares, Issued for Services	2,173,914
Shares Issued, Price Per Share | $ / shares										$ 2			$ 2
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 0.50				$ 0.02						$ 0.50		$ 0.50			$ 0.50
Class of Warrant or Right, Outstanding		1,230,674										1,230,674		1,230,674
Warrants Intrinsic Value | $														$ 3,860,723
Share Price | $ / shares		$ 4							$ 2.30			$ 4		$ 4
Stock Issued During Period, Value, New Issues | $														$ 850,000	5,000,001
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares														250,000
Debt Conversion, Original Debt, Amount | $																$ 535,149
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate														2.46%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate														115.00%
Stock Issued | $														$ 0	$ 308,628
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value | $							$ 62,500		$ 143,750					$ 399,716
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number		100,000						250,000				100,000		100,000	400,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value | $		$ 249,777										$ 249,777		$ 249,777
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross									62,500					250,000
Stock Issued During Period, Shares Warrants Exercised		30,000				73,000
Stock Issued During Period, Value Warrants Exercised | $		$ 15,000				$ 1,460								$ 16,460
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares		62,500								300,000		62,500	300,000	62,500
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options | $		$ 225,000										$ 225,000		$ 225,000	$ 658,383
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares							$ 2.50
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period							5 years			5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | $		$ 2,368,750										$ 2,368,750		2,368,750
Preferred Stock, Capital Shares Reserved for Future Issuance																		10,000,000
Number Of Warrants Expired				15,119	75,503
Number Of Warrants Subject To Term Extension				186,424	201,543
Investment Warrants, Exercise Price | $ / shares											$ 2
Investment Warrants Expiration Date				May 31, 2019
Fair Value Adjustment of Warrants | $														1,621,397	0
Stock or Unit Option Plan Expense | $														656,735
Number Of Warrants With Extended Expiration Date																	300,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value | $															256,754
Allocated Share-based Compensation Expense | $														$ 1,595,037	$ 2,115,319
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period															81,250
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price | $ / shares		$ 2.50										$ 2.50		$ 2.50
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term														3 years
General and Administrative Expense [Member]
Class of Warrant or Right [Line Items]
Allocated Share-based Compensation Expense | $														$ 1,595,037	$ 2,094,334
Selling and Marketing Expense [Member]
Class of Warrant or Right [Line Items]
Allocated Share-based Compensation Expense | $														0	20,357
Research and Development Expense [Member]
Class of Warrant or Right [Line Items]
Allocated Share-based Compensation Expense | $														$ 0	$ 628
Private Placement [Member]
Class of Warrant or Right [Line Items]
Common Stock, Par or Stated Value Per Share | $ / shares	$ 0.001	0.001										$ 0.001		$ 0.001
Stock Issued During Period, Shares, Issued for Services	2,173,914											369,567
Shares Issued, Price Per Share | $ / shares	$ 2.30	$ 2.30										$ 2.30		$ 2.30
Share Price | $ / shares	$ 4
Proceeds from Issuance of Private Placement | $	$ 5,000,001											$ 850,000
Non Qualified Stock Options [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares										325,000				394,239
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross										625,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period									10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number		625,000										625,000		625,000
Non Qualified Stock Options [Member] | Consultant [Member]
Class of Warrant or Right [Line Items]
Share Price | $ / shares								$ 2.50
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares								125,000						250,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value | $								$ 312,275
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross								375,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options | $		$ 413,877										$ 413,877		$ 413,877
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number		375,000										375,000		375,000
July 2018 Options [Member]
Class of Warrant or Right [Line Items]
Shares Issued, Price Per Share | $ / shares		$ 2.50										$ 2.50		$ 2.50
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares			12,500					50,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value | $			$ 44,994
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value | $		$ 149,939										$ 149,939		$ 149,939
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			50,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares		37,500										37,500		37,500
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options | $		$ 130,187										$ 130,187		$ 130,187
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period								5 years
Warrant [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 0.71			$ 2							$ 0.71		$ 0.71
Warrants Weighted Average Remaining Life														3 months 18 days
Restricted Stock [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Shares, Issued for Services																176,250
Share Price | $ / shares															$ 1.76
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value | $															$ 143,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value | $															$ 256,754
Stock Issued During Period, Value, Issued for Services | $																$ 113,754
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period															81,250
Share-based Compensation Award, Tranche One [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares			37,500				125,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value | $										$ 486,070
Share-based Compensation Award, Tranche Two [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares			25,000				62,500
Share-based Compensation Award, Tranche Three [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares			12,500				287,500
Common Stock [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation | $															$ 401,037
Stock Issued During Period, Shares, Issued for Services															243,400
Stock Issued During Period, Shares, New Issues														369,567	2,173,914
Stock Issued During Period, Value, New Issues | $														$ 370	$ 2,174
Stock Issued During Period, Shares Warrants Exercised														103,000
Stock Issued During Period, Value Warrants Exercised | $														$ 102
Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Debt Conversion, Converted Instrument, Shares Issued																535,154
Stock Issued | $																$ 784,888
Maximum [Member]
Class of Warrant or Right [Line Items]
Share Price | $ / shares				$ 4											$ 4
Maximum [Member] | Measurement Input, Price Volatility [Member]
Class of Warrant or Right [Line Items]
Warrants and Rights Outstanding, Measurement Input				119
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Class of Warrant or Right [Line Items]
Warrants and Rights Outstanding, Measurement Input				2.89
Minimum [Member]
Class of Warrant or Right [Line Items]
Share Price | $ / shares		$ 1.76		$ 2.30								$ 1.76		$ 1.76
Minimum [Member] | Measurement Input, Price Volatility [Member]
Class of Warrant or Right [Line Items]
Warrants and Rights Outstanding, Measurement Input				118
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Class of Warrant or Right [Line Items]
Warrants and Rights Outstanding, Measurement Input				2.61
Series A Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Shares Issued, Price Per Share | $ / shares																$ 1
Share Price | $ / shares																$ 1
Stock Issued During Period, Shares, New Issues														0	0	1,170,000
Stock Issued During Period, Value, New Issues | $														$ 0	$ 0	$ 1,170,000
Preferred Stock, Dividend Rate, Percentage																8.00%
Preferred Stock, Dividends Per Share, Declared | $ / shares																$ 1.20
Common Stock Dividends, Shares															101,962
Dividends, Preferred Stock, Stock | $															$ 122,328
Stock Issued During Period, Shares Warrants Exercised														0
Stock Issued During Period, Value Warrants Exercised | $														$ 0
Series B Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Share Price | $ / shares										$ 1			$ 1
Stock Issued During Period, Shares, New Issues													3,105,000	0	0
Stock Issued During Period, Value, New Issues | $													$ 3,105,000	$ 0	$ 0
Preferred Stock, Dividend Rate, Percentage													6.00%
Preferred Stock, Dividends Per Share, Declared | $ / shares													$ 1.50
Common Stock Dividends, Shares															124,219
Convertible Preferred Stock, Shares Issued upon Conversion	3,490,977
Stock Issued During Period, Shares Warrants Exercised														0
Stock Issued During Period, Value Warrants Exercised | $														$ 0
Series B Preferred Stock [Member] | Dividend Declared [Member]
Class of Warrant or Right [Line Items]
Dividends, Preferred Stock, Stock | $															$ 186,300

Related Party Transactions (Det

Related Party Transactions (Details Textual) - USD ($)	Nov. 03, 2017	Sep. 30, 2017	Sep. 29, 2017	Dec. 31, 2018	Dec. 31, 2017
Related Party Transaction [Line Items]
Due to Related Parties, Current				$ 0	$ 146,133
Related Party Transaction, Terms and Manner of Settlement		3
Stock Issued During Period, Shares, Issued for Services	2,173,914
Equity Method Investment, Ownership Percentage			11.00%
Related Party Transaction, Description of Transaction			entitled to compensation of $10,000 per month.
VectorVision Inc [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, Issued for Services		1,525,000
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Payments to Employees					170,000
David W. Evans [Member] | VectorVision Inc [Member]
Related Party Transaction [Line Items]
Equity Method Investment, Ownership Percentage		28.00%
Tamara Evans [Member] | VectorVision Inc [Member]
Related Party Transaction [Line Items]
Equity Method Investment, Ownership Percentage		72.00%
General and Administrative Expense [Member] | Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Officers' Compensation				$ 275,000	$ 250,000

Income Taxes (Details)

Income Taxes (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Net operating loss carryforwards	$ 2,689,000	$ 1,551,000
Stock-based compensation	942,000	504,000
Amortization of intangibles	19,000	0
Accrued compensation	0	17,000
Depreciation	(1,000)	5,000
Total deferred tax assets	3,649,000	2,077,000
Valuation allowance	(3,649,000)	(2,077,000)
Net deferred tax assets	$ 0	$ 0

Income Taxes (Details 1)

Income Taxes (Details 1)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
U. S. federal statutory tax rate	(21.00%)	(35.00%)
Non-deductible stock-based compensation	0.00%	4.30%
Non-deductible fair value of warrant extensions	4.40%	0.00%
Expirations related to stock-based compensation	0.10%	0.00%
Adjustment to deferred tax asset	0.40%	68.50%
Change in valuation allowance	16.00%	(38.00%)
Other	0.10%	0.20%
Effective tax rate	0.00%	0.00%

Income Taxes (Details Textual)

Income Taxes (Details Textual)	12 Months Ended
	Dec. 31, 2018USD ($)
Operating Loss Carryforwards	$ 9,945,000
Operating Loss Carryforwards Expiration Year	2,035

Subsequent Events (Details Text

Subsequent Events (Details Textual) - USD ($)	1 Months Ended
	Feb. 11, 2019	Jan. 30, 2019	Dec. 31, 2018	Sep. 21, 2018	Jan. 31, 2018	Dec. 31, 2017
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.50	$ 0.50	$ 0.02
Common Stock, Par or Stated Value Per Share			$ 0.001			$ 0.001
Subsequent Event [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.50
Common Stock, Par or Stated Value Per Share		$ 0.001
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	312,500
Proceeds from Issuance of Warrants	$ 31,250